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The epidermal growth factor receptor (EGFR) is a gene expressed in epithelial cells and 
is involved in a variety of diseases, including preeclampsia, intrauterine growth restriction, 
embryonic lethality, diabetes, cardiac dysfunction, poxvirus propagation, and tumorigenesis. 
EGFR is a member of the ERBB family of receptor tyrosine kinases, consisting of EGFR/HER1, 
ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4, and is a central point in an extensive network 
of growth-promoting intracellular signaling pathways, making it a prominent inducer of cellular 
proliferation and survival. Since EGFR is often co-opted by cancer cells through up-regulation of 
the receptor’s expression and/or activity, there are several EGFR-targeted anti-cancer therapies 
used in the clinic and many more currently being explored in preclinical and clinical trials. Any 
potential cardiotoxicity rates for such therapies are unknown. Here we demonstrate that a 
subgroup in the population, those at risk of dilated cardiomyopathy, may experience severe 
adverse effects to EGFR inhibitors. BALB/cJ male mice treated with the EGFR tyrosine kinase 
inhibitor AG1478 had an exacerbated increase in left ventricular mass. Our findings support the 
utility of using genetically diverse mouse models to identify at risk groups. We also demonstrate 
genetic background-dependent differences in baseline cardiac structure and function, as well as 
differences in cardiac aging across four mouse strains (A/J, BALB/cJ, C57BL/6J, and FVB/NJ). 
We explored the utility of EGFR pharmacological inhibition in cancer prevention by exposing 
mice to AG1478 for 16 months. This timeframe allowed the mice to develop a variety of 
spontaneous neoplasia, with pulmonary adenomas being the most prominent neoplasm. Our 
findings demonstrate that EGFR-targeted treatment was ineffective for chemoprevention in a 
model of spontaneous somatic mutations in genetic backgrounds with familial risks of cancer. 
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Although our findings suggest that EGFR-targeted treatment is not beneficial for 
chemoprevention in the general population, high risk individuals with specific mutations or pre-






Many people supported me throughout my graduate school journey that I want to thank. I 
would like to thank past and present members of the Genetics Program and Threadgill Lab for 
being my friends, for putting much effort and time into helping me with my work when I really 
needed it, and for simply being supportive. I am forever indebted to my advisor, Dr. David 
Threadgill. He put together a wonderful lab “family”, and his combination of wisdom, intuition, 
and sincere kindness are unmatched. I am grateful to Dr. Bankaitis for his sincere advice, and for 
listening to me when I needed help finding my research path again. Much appreciation is due to 
my thesis committee for helping me grow as a scientist and for their support in allowing me to 
change projects when the original one was not working out as planned. The undergraduate 
researchers in the lab (Thank you Team Baymax, and others) helped me tremendously with 
gathering data and helping make this work move forward. I am extremely grateful to my 
Fernandez & Howe family for always believing in me. I especially want to thank my husband, 
Russell, who has supported me fully in all that I do, and has spent countless hours listening to me 
prepare. I am grateful to my parents Israel and Yolanda who have always supported me and have 
taught me by example how to be a self-motivated and methodical thinker.  
 
 v 
CONTRIBUTORS AND FUNDING SOURCES 
 
Contributors 
 This work was supervised by a thesis committee consisting of Professors David W. 
Threadgill (thesis advisor) and Vytas A. Bankaitis of the Department of Molecular and Cellular 
Medicine, Professor Fuller W. Bazer of the Department of Animal Science, and Professor Mark 
E. Westhusin of the Department of Veterinary Physiology and Pharmacology. 
 The analysis for the cardiac histology slides was provided by Doctor Maureen O’Brien 
from Charles River Laboratories. Doctor Amie Perry, from the Department of Veterinary 
Pathobiology, analyzed the neoplasia histology samples. Doctor Steve Leung at the University of 
Kentucky provided his expert opinion on interpreting the physiological significance of the 
ultrasound data.  
 All other work conducted for the thesis was completed by the student independently. 
Funding Sources 





TABLE OF CONTENTS 
  Page 
ABSTRACT .................................................................................................................................... ii 
ACKNOWLEDGEMENTS ........................................................................................................... iv 
CONTRIBUTORS AND FUNDING SOURCES .......................................................................... v 
TABLE OF CONTENTS ............................................................................................................... vi 
LIST OF FIGURES ..................................................................................................................... viii 
LIST OF TABLES .......................................................................................................................... x 
CHAPTER I  INTRODUCTION TO THE ROLE OF MISREGULATED EGFR SIGNALING 
IN CANCER AND CARDIOMYOPATHY .................................................................................. 1 
Introduction .............................................................................................................................................. 1 
Availability of EGFR ligands ................................................................................................................... 3 
Concentration of EGFR on the cellular membrane .................................................................................. 6 
Activating mutations ............................................................................................................................... 11 
Cross-talk among kinases and activation of alternative pathways ......................................................... 14 
Misregulated endocytosis of EGFR ........................................................................................................ 19 
Cardiac hypertrophy ............................................................................................................................... 21 
EGFR signaling pathways involved in cardiomyopathies ...................................................................... 23 
EGFR genetic modifiers ......................................................................................................................... 30 
Specificity of EGFR inhibitors ............................................................................................................... 31 
Conclusions ............................................................................................................................................ 32 
References .............................................................................................................................................. 38 
CHAPTER II  INHIBITION OF EGFR BY AG1478 AUGMENTS HYPERTROPHY IN AGED 
BALB/CJ MICE WITH DILATED CARDIOMYOPATHY ....................................................... 59 
Introduction ............................................................................................................................................ 59 
Materials and Methods ........................................................................................................................... 63 
Results .................................................................................................................................................... 67 
Discussion ............................................................................................................................................... 74 





CHAPTER III  INHIBITION OF EGFR BY AG1478 REDUCES INCIDENCE OF  
     SPONTANEOUS PULMONARY ADENOMAS IN A/J FEMALE MICE ......................... 118 
Introduction .......................................................................................................................................... 118 
Materials and Methods ......................................................................................................................... 123 
Results .................................................................................................................................................. 124 
Discussion ............................................................................................................................................. 126 
References ............................................................................................................................................ 135 
CHAPTER IV  CONCLUSIONS AND FUTURE DIRECTIONS ............................................ 141 
Conclusions .......................................................................................................................................... 141 
Future Directions .................................................................................................................................. 143 





LIST OF FIGURES 
Page 
Figure 1.1.    Diagram of EGFR protein. ...................................................................................... 35 
Figure 1.2.    Diagram of cardiac concentric and eccentric hypertrophies ................................... 36 
Figure 1.3.    Adaptation of a cancer cell population to targeted treatment .................................. 37 
Figure 2.1.    Genetic background-dependent differences in baseline echocardiographic               
                      parameters ............................................................................................................... 78 
Figure 2.2.    Age-related cardiovascular changes vary by genetic background .......................... 79 
Figure 2.3.    Age-related changes in cardiac function and structure in the A/J genetic               
                      background .............................................................................................................. 80 
Figure 2.4.    Age-related changes in cardiac function and structure in the BALB/cJ               
                      genetic background ................................................................................................. 81 
Figure 2.5.    Age-related changes in cardiac function and structure in the C57BL/6J               
                      genetic background ................................................................................................. 82 
Figure 2.6.    Age-related changes in cardiac function and structure in the FVB/NJ genetic               
                      background .............................................................................................................. 83 
Figure 2.7.    Treatment with AG1478 exacerbates severity of dilated cardiomyopathy ............. 84 
Figure 2.8.    No significant changes in body and fat mass .......................................................... 85 
Figure 2.9.    No significant differences in body weight and fat mass among female mice               
                      separated by strain................................................................................................... 86 
Figure 2.10.  No significant differences in body weight and fat mass among male mice               




Figure 2.11.  Kaplan-Meier survival curves for mice separated by strain and sex ....................... 88 
Figure 2.12.  Increased splenomegaly among treated mice .......................................................... 89 
Figure 3.1.    Reduced incidence of pulmonary adenoma in A/J female mice ........................... 129 
Figure 3.2.    Fast growing smooth muscle sarcoma in a representative A/J mouse .................. 130 





LIST OF TABLES 
Page 
Table 2.1.    Genetic background-dependent differences in body composition and               
                     echocardiographic parameters ................................................................................. 90 
Table 2.2.    Correlation coefficients (r) for the A/J mouse strain across four time               
                     points (4, 8, 12, and 16-month points) ..................................................................... 91 
Table 2.3.    Correlation coefficients (r) for the BALB/cJ mouse strain across four                
                     time points (4, 8, 12, and 16-month points) ............................................................. 92 
Table 2.4.    Correlation coefficients (r) for the C57BL/6J mouse strain across four               
                     time points (4, 8, 12, and 16-month points) ............................................................. 93 
Table 2.5.    Correlation coefficients (r) for the FVB/NJ mouse strain across four time               
                     points (4, 8, 12, and 16-month points) ..................................................................... 94 
Table 3.1.    Pulmonary adenoma frequency for A/J mice ......................................................... 131 
Table 3.2.    Pulmonary adenoma frequency for BALB/cJ mice ................................................ 132 
Table 3.3.    Pulmonary adenoma frequency for FVB/NJ mice .................................................. 133 
Table 3.4.    Sarcoma frequency for A/J mice ............................................................................ 134 
 
 1 
CHAPTER I  
INTRODUCTION TO THE ROLE OF MISREGULATED EGFR SIGNALING IN 
CANCER AND CARDIOMYOPATHY 
 
Introduction  
 The epidermal growth factor receptor (EGFR) is a gene expressed in epithelial 
cells and is critical for early development as well as tissue maintenance in adults. EGFR 
(also known as HER1) is the prototypical member of the ERBB family of tyrosine 
kinases and is a central point in an extensive network of growth-promoting intracellular 
signaling pathways, making it a strong inducer of cellular proliferation and survival. 
Disruption of these complex interactions at the level of extracellular signaling (i.e. 
EGFR mis-regulation) is implicated in a variety of diseases, including preeclampsia, 
intrauterine growth restriction, embryonic lethality, diabetes, cardiac dysfunction, 
poxvirus propagation, and tumorigenesis. Misregulation of EGFR activity is implicated 
in an array of cancers, with hyperactivity observed in about one-third of carcinomas 
(Mendelsohn, 2002). There are several EGFR-targeted antibodies and small molecule 
tyrosine kinase inhibitors (TKIs) currently approved by the Food and Drug 
Administration (FDA) for cancer treatment. Cancer patients are typically exposed to 
EGFR-targeted therapy for long periods of time that can range from months to several 
years. Extensive data has shown that chronic exposure to other chemotherapeutics, such 
as anthracyclines, can induce cardiotoxicity and heart failure at alarming rates. Such 
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findings have stressed the importance of monitoring for cardiotoxicity of 
chemotherapeutics in preclinical trials.  
 The exact function of EGFR in the adult heart remains to be determined. Mouse 
models that inhibit, knockout, or overexpress downstream effectors of EGFR have 
hinted at potential roles in cardiac hypertrophy, fibrosis, and response to stress. Given 
the long-term nature of EGFR-targeted therapy and the adverse cardiac effects 
associated with inhibiting signaling pathways downstream of EGFR, there is a strong 
need to understand EGFR's role in the heart for the purposes of cardiotoxicity avoidance. 
This information is especially critical if EGFR inhibition were to be used in long-term 
preventative medicine. Studies from our group and others have shown a strong benefit to 
reduced EGFR signaling in mouse models of colorectal cancer. Whether it be 
pharmacological inhibition or the use of the EGFRwa2 hypomorphic allele, studies have 
reported 50-90% reductions in tumor load (Rinella & Threadgill, 2012; Roberts et al., 
2002). Such findings implicate EGFR inhibitors as possible chemopreventative agents. 
Given the wide range of cancers with hyperactive EGFR signaling, pharmacological 
inhibition of EGFR may be beneficial in other cancer prevention models.  
 Given that hyperactivity of growth-promoting pathways often has devastating 
consequences on the well-being of the organism, EGFR has evolved multiple 
mechanisms of regulation. EGFR can be categorized into three overarching domains: the 
extracellular ligand binding domain, the transmembrane domain, and the intracellular 
kinase domain. Interactions between the different components permit EGFR to be 
primed for activation while conversely it can be signficiantly inhibited during times 
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when activity is inappropriate. Here we briefly describe the activating and inhibitory 
functions of each domain and the ways that these functions are dysregulated in cancer 
cells. This review emphasizes that a detailed understanding of how cancer exploits 
EGFR is key to tailoring treatments and informative for the design of prevention studies. 
We examine why different EGFR-targeted treatments have had varying levels of success 
in treating cancers and the implications that such therapies might have on cardiovascular 
health as we integrate several cardiology studies involving the EGFR signaling network 
in an attempt to elucidate the potential functional roles of EGFR in the adult heart. 
 
Availability of EGFR ligands  
 There are seven known growth factors that bind to EGFR’s ligand binding 
domain: epidermal growth factor (EGF), heparin binding EGF-like growth factor (HB-
EGF), transforming growth factor-α (TGFα), amphiregulin, betacellulin, epigen, and 
epiregulin (Singh et al., 2016). The growth factors all have a sequence of six cysteine 
residues with conserved spacing that allows them to bind to EGFR. The ligands must be 
cleaved from the cellular membrane by metalloproteinases. Once cleaved, the ligands are 
soluble and can activate EGFR in endocrine, paracrine, and autocrine fashions (Prenzel 
et al., 1999; Schneider & Wolf, 2009). There is growing data demonstrating/suggesting 
that ligands can also remain bound to the cell membrane and bind to EGFR in a 
juxtacrine manner (Schneider & Wolf, 2009).  
 Upon ligand binding to EGFR's extracellular domain, the receptor dimerizes with 
another EGFR molecule or another ERBB family member though a ligand-binding 
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conformational change that exposes the dimerization arm (Burgess et al., 2003; Endres 
et al., 2014). Dimerization is entirely receptor-mediated, with the ligands being on the 
outer ends of the dimer and therefore not making direct contact with the dimerization 
interface (Lemmon & Schlessinger, 2010). Receptor dimerization does not always 
require bound ligand, as studies have shown that that a significant portion of inactive 
EGFR receptors exist in the dimer conformation (Figure 1.1). Ligand binding triggers 
the kinase domains to change from a symmetrical orientation to an active asymmetric 
position (Purba et al., 2017). The EGFR inhibitor cetuximab preferentially binds 
untethered EGFR and sterically blocks the extension of the dimerization arm (Li et al., 
2005). Conversely, this mechanism of action may contribute to resistance to cetuximab 
therapy in general as this inhibitor would have very limited effect in an environment 
where EGFR receptors are already dimerized. In normal cells, ligand availability tends 
to be short-lived and well controlled, ensuring that EGFR activation only occurs 
transiently and in response to specific stimuli.   
 In cancer cells, overexpression of EGFR ligands promotes EGFR activity and 
tumor growth, such as the overexpression of epiregulin and amphiregulin in cases of 
metastatic colorectal cancer (Khambata-Ford et al., 2007) and overexpression of TGFα 
found in several types of cancers (Chakraborty et al., 2014; Grandis et al., 1998; Sasaki 
et al., 2013; Umekita et al., 2000). Cancers that rely on ligand-dependent EGFR 
signaling tend to be responsive to treatment with EGFR tyrosine kinase inhibitors (TKIs) 
(Chakraborty et al., 2014; Khambata-Ford et al., 2007; Schiff et al., 2004). Elevated 
levels of both HB-EGF transcript and protein are a common finding in ovarian cancer, 
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with anti-HB-EGF antibodies showing promise in preclinical anti-cancer trials but 
demonstrating significant neurotoxicity in the initial clinical trial (Miyamoto et al., 2004; 
Sarantopoulos et al., 2016). Current therapies focus on antibodies against the ligands at 
the protein level as well as inhibition of the metalloproteinases that cleave ligands. 
Inhibition of ligands at the transcript level may be a possible route to explore for 
correcting situations where excess ligand is driven by high transcript levels and/or by 
gene amplification.  
 Non-EGFR-targeted treatments are also used to more directly target the source of 
excessive ligand release. G-protein coupled receptors (GPCRs) are known to promote 
metalloproteinase cleavage of ligands bound at the cellular membrane. Accordingly, 
misregulation of GPCRs is implicated in cancers, partly due to their roles in promoting 
excessive release of EGFR ligands (Almendro et al., 2010; Yu et al., 2018). The proto-
oncogene, SRC, is a non-receptor tyrosine kinase that has functions both upstream and 
downstream of EGFR and is a conduit of GPCR signaling due to its role in activating 
metalloproteinases. For instance, GPR30 is a GPCR that promotes SRC activity and 
subsequent SRC-mediated cleavage of HB-EGF in an estrogen-mediated manner that is 
implicated in estrogen-receptor-negative breast cancer (Filardo, 2002; Filardo & 
Thomas, 2005). SRC may also be involved in hyperactivation of EGFR without GPCR 
involvement. Maretzky et al. (2011) showed that a constitutively active Src mutation 
promotes metalloproteinase-mediated shedding of TGFα and subsequent activation of 
EGFR signaling pathways, the effects of which were blocked with inhibitors of either 
SRC, the metalloproteinase (ADAM17) or EGFR. Taken together, both GPCRs and 
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SRC may be underappreciated yet potential targets for cancer mitigation. GPCRs, in 
particular, are popular targets for treatment of cardiovascular conditions but have largely 
been unexplored in cancer therapy (Belmonte & Blaxall, 2012; Yu et al., 2018). There 
are multiple other mechanisms not discussed here that promote ligand cleavage and are 
potential targets for therapy. For instance, hyperactivity of lysophosphatidic acid is 
associated with ovarian, breast, and prostate cancers, with the mechanism consisting of 
promotion of metalloproteinase activity, and subsequent excessive shedding of HB-EGF 
(David et al., 2014; Fishman et al., 2001; Willier et al., 2013).  
 Currently, immunotherapy against EGF is being explored as an option for 
treating non-small-cell lung carcinoma. The anti-EGF vaccine CIMAvax-EGF has been 
shown to be efficacious in multiple clinical trials of advanced stage IIIB/IV non-small-
cell lung carcinoma (NSCLC) (Rodriguez et al., 2016; Rodriguez et at., 2010; Saavedra 
& Crombet, 2017). The large response rates reported in these clinical trials (>50%) 
indicate the importance of tailoring treatments to individual biomarkers in order to 
improve treatment, as efficacy correlated strongly with serum EGF concentrations 
(Saavedra & Crombet, 2017).  
 
Concentration of EGFR on the cellular membrane 
 The intracellular component of EGFR consists of a juxtamembrane segment, the 
catalytically active kinase domain, and the C-terminal tail containing multiple tyrosine 
residues. In the monomer and/or inactive states, the positively charged kinase domain 
docks to the plasma membrane by electrostatic interactions with the negative charge 
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from both the plasma membrane and the receptor's juxtamembrane segment (Arkhipov et 
al., 2013). This inactive configuration is key to sterically inhibiting dimerization 
between adjacent ERBB receptors during times when EGFR activity is inappropriate 
(Endres et al., 2013). In the active state, the transmembrane domains from the two 
ERBB receptors dimerize at the N-terminus, the juxtamembrane segment undocks from 
the cellular membrane and helps interlock the two kinase domains, and the kinase 
domain forms an asymmetric dimer that allows for the commencement of an 
autophosphorylation cascade (Arkhipov et al., 2013; Kovacs et al., 2015; Zhang et al., 
2006). In the C-terminal tail, the receptors’ tyrosine residues capture phosphate groups, 
creating phosphotyrosine binding docks at which other proteins and complexes can 
become phosphorylated and form complexes (Burgess et al., 2003; Endres et al., 2014). 
These interactions at the tyrosine residues result in a cascade of signaling pathways, 
among which the ERK, PI3K/AKT, STAT3, JNK and p38 MAPK signal transduction 
pathways are activated. There are many factors that coalesce to determine which 
pathways are activated, including but not exclusive to the type of ligand bound at the 
ligand binding domain and their relative availabilities, the mode of ligand binding 
(juxtacrine, paracrine, and so forth), and the dimerization partner of EGFR (each 
receptor has different combinations of binding docks) (Singh & Harris, 2005). Although 
EGFR activation is primed by the ability of dimers to readily become phosphorylated, 
95% of EGFR receptors on the cell membrane are estimated to be in the inactive non-
ligand bound state (Burgess et al., 2003; Johns et al., 2004). This demonstrates how 
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tightly EGFR activation is controlled by the cell, given how devastating hyperactivity 
can be to the overall organism.  
 The extracellular, transmembrane, and intracellular components of EGFR all 
cooperate to inhibit phosphorylation in the absence of a bound ligand. The 
transmembrane helix, often thought to be passive, has been shown to be crucial in 
maintaining the juxtamembrane segment docked to the plasma membrane (Endres et al., 
2013). The inactive configuration of the extracellular component sterically blocks 
interaction between ERBB transmembrane domains by promoting dimerization at the C-
terminal rather than the N-terminal configuration associated with activation. When the 
extracellular component is deleted or when there are flexible glycine-serine-threonine 
linkers, EGFR activity is extremely high despite there being no ligand bound (Endres et 
al., 2013). Both situations remove the steric block associated with the inactive/tethered 
extracellular domain, permitting receptor dimerization. Overexpression of EGFR can 
overcome inhibitory mechanisms by being a source of ligand-independent activity, given 
that high cell surface densities of EGFR stimulate phosphorylation even in the absence 
of ligands (Endres et al., 2013), indicating that crowding of receptors can overcome the 
inhibitory mechanisms intrinsic to the non-ligand-bound EGFR. High concentrations of 
EGFR enhance dimerization of the kinase domains and consequently trigger catalytic 
activity.  
 Although electrostatic interactions and ligand-dependent configurations help 
maintain EGFR in the inactive state, these mechanisms of inactivation are often 
disrupted in cancers via mutations in the EGFR gene. In glioblastoma, the most 
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prevalent type of brain cancer, more than 50% of tumors have amplification of the 
EGFR gene. Consequently, receptor overexpression and gene rearrangements are 
common occurrences (Chakraborty et al., 2014). Cancer cells further exploit receptor 
overcrowding by tampering with the extracellular domain's inhibitory functions. The 
EGFR version III mutation (EGFRvIII) is a gene rearrangement with deletions in the 
extracellular domain (exons 2-7). EGFRvIII is the most common EGFR mutation in 
glioblastoma, reported in 20-30% of cases, and has been found to a lesser extent in 
mammary carcinoma and non-small cell lung carcinoma (Gan et al., 2013). Despite the 
inability of EGFRvIII to bind ligands, these mutant receptors have low level activity. 
This activity may be caused by the absence of extracellular steric pressure, which under 
normal conditions blocks interactions between receptors, thereby inhibiting spontaneous 
kinase dimerization. The truncated extracellular domain in the EGFRvIII mutant 
receptor may be permissive to escaping steric inhibitory pressure. This mutation is 
particularly potent when accompanied by an environment of high density EGFR 
receptors on the cell membrane (i.e. overexpression) that is typical of gene amplification.  
 Several approaches have been tested in preclinical trials to target EGFRvIII 
mutant receptors, including immunotherapy, RNA-based therapies, and antibodies 
(Padfield et al., 2015). Immunotherapy (with dendritic cells carrying information on 
EGFRvIII specific peptides) has had success in eliminating EGFRvIII mutant-expressing 
cells in vitro but is largely lethal in in vivo mouse studies and undeliverable across the 
blood brain barrier with current methods (Padfield et al., 2015; Sampson et al., 2008). 
Rindopepimut, a vaccine against EGFRvIII, was reported to be ineffective and 
 
 10 
potentially harmful in Phase III clinical trials, with the treatment group having slightly 
lower survival time than the control group (Weller et al., 2017). Other immunotherapies 
have consisted of using CAR T-cells to recognize antigens specific to EGFRvIII-
expressing tumors, and is currently being evaluated in an initial clinical trial (Yang et al., 
2017). Antibody therapy, in particular of ABT-414, is currently being tested in clinical 
trials, with the most recently completed trial reporting a 28.8% six-month progression 
free response rate (van den Bent et al., 2017; Yang et al., 2017). 
 Tumors highly expressing EGFR have a wide range of response to EGFR-
targeted treatments. For instance, anaplastic thyroid cancer overexpressing EGFR is 
highly responsive to Gefinitib both in human cells in vitro and with an in vivo mouse 
model of thyroid carcinoma (Schiff et al., 2004). A Phase II clinical trial was recently 
completed (NCT00095836) but results are not yet published. In contrast, EGFR 
overexpression in breast cancer is generally resistant to treatment with EGFR inhibitors, 
likely due to functional redundancies shared with ERBB2, which can also promote 
MEK/ERK and PI3K/AKT signaling. Although EGFR TKIs may in part help with 
sequestering ERBB2 (Arteaga et al., 2005), signaling via ERBB2 could still persist by 
ERBB2-ERBB3 or ERBB2-ERBB4 heterodimers - a likely scenario given that ERBB2 
is highly expressed in about 30% of breast cancers (Slamon et al., 1987). For these 
reasons, EGFR inhibitors are commonly used in conjunction with other 
chemotherapeutics, such ERBB2 inhibitors in treatment of breast cancer, a combination 
also explored in treating gastric, pancreatic and head and neck cancers (Gray et al., 2017; 
Larbouret et al., 2012; Wainberg et al., 2010). These experiments show that detailed 
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analyses of tumor biomarkers that consider signal transduction redundancies inherent to 




 The vast majority of EGFR mutations are somatic, with 93% of mutations 
occurring in the first four exons (exons 18-21) of the kinase domain (Kobayashi & 
Mitsudomi, 2016; Siegelin & Borczuk, 2014). Mutations in the tyrosine kinase domain 
of the EGFR gene are particularly common in NSCLC, with about 10-12% incidence in 
the United States and over 50% incidence in East Asian populations. The del746-750, 
which is an exon 19 inframe deletion of 4 amino acids, accounts for about 45% of the 
mutations in NSCLC, whereas the L858R missense mutation in exon 21 accounts for 
40% (Kobayashi & Mitsudomi, 2016). Both of these mutations have been reported to 
encourage dimerization at the kinase domain, allowing for tyrosine activity without 
upstream ligand binding (Okabe et al., 2007). EGFR amplification is not a requirement 
for mutant-induced activation (Okabe et al., 2007), meaning that overexpression may not 
be the mechanism permitting dimerization. The likely mechanism is by conformational 
changes induced by the mutations that facilitate dimerization in the absence of ligand 
(Arteaga et al., 2005; Okabe et al., 2007). In fact, even bound EGFR inhibitors, such as 
AG1478, trigger conformational changes that facilitate receptor dimerization and 
formation of inactive dimers (Arteaga et al., 2005). The exon 19 deletion and L858R 
mutations have a 60% response rate to EGFR TKIs (Kobayashi & Mitsudomi, 2016). In 
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fact, non-smoking East Asian females with lung adenocarcinoma, a group with a 
particularly high incidence of activating EGFR mutations (Shi et al., 2014; Shigematsu 
et al., 2005), tend to respond favorably to EGFR-targeted therapy (Yang, 2008; Yang et 
al., 2014). 
 Cancers often develop resistance to EGFR TKI treatment, with the T790M 
EGFR missense mutation at exon 20 accounting for over 60% of NSCLC TKI-resistant 
cases (Yu et al., 2013). The T790M mutation has been shown to have higher ATP 
affinity, thus making it a potent competitor against small molecular inhibitors and a 
common mechanism of tumor resistance to therapy. Sharma et al. (2007) postulate that 
the T790M mutation may have a two-fold advantage to cancer cells, occurring early in 
tumorigenesis to enhance tumor outgrowth and later providing a selective advantage 
against EGFR TKI treatment. Ultimately, EGFR-targeted treatments are thought to fail 
due to tumor heterogeneity, in which selective pressure by TKIs such as gefinitib 
inadvertently promotes persistence of a subgroup of cells harboring the T790M 
mutation. More recently, the third generation inhibitors osimertinib and olmutinib were 
designed to target T790M mutant receptors by forming covalent bonds at the tyrosine 
residues. However, the problem of selective pressure persists, with the C797S mutation 
(in trans to T790M) conferring resistance to these inhibitors by disrupting the covalent 
bond with the TKI. Fortunately, the C797S mutation is sensitive to first generation TKIs 
(such as gefinitib and erlotinib) and combinatorial therapy of first and third generation 
TKIs were shown to be beneficial at treating both mutations simultaneously in multiple 
preclinical trials (Kobayashi & Mitsudomi, 2016; Li et al., 2017). These findings 
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highlight the significance of sampling the cell population and targeting multiple 
mutations in order to minimize a selective advantage, although even this technique has 
limits. Combinatorial therapy with first and third generation TKIs was applied clinically 
to a patient with advanced lung adenocarcinoma and was reported to be initially 
effective in stopping tumor progression. However, the tumor cell population transitioned 
to an in cis preference for the C797S mutation, re-enabling resistance to therapy (Wang 
et al., 2017). 
 There is an abundance of rare mutations in pulmonary adenocarcinomas that 
trigger ligand-independent EGFR activity not covered here but well documented in 
reviews such as Siegelin & Borczuk (2014). An understanding of the gain-of-function 
properties of each mutation would aid in designing optimally-targeted therapies and 
improve response to treatment. For instance, first generation TKIs are generally more 
effective on the exon 19 deletion than on the L858R mutation. An understanding of the 
functional difference between the two types of mutations and their interactions with the 
TKIs would aid in the design of future therapies tailored to specific mutations. For 
example, a functional study investigated why treatment with cetuximab (an EGFR 
monoclonal antibody that binds to the extracellular domain) is not effective with certain 
EGFR mutations, such as the dual L858R/T790M mutation (Cho et al., 2013). The study 
demonstrated the functional role of cetuximab in preventing dimer formation, explaining 
why cetuximab is effective with certain mutations (i.e. that still depend on receptor 
dimerization for kinase activity) but not with the mutations associated with resistance to 
therapy (i.e. the mutant receptors that can be catalytically active as monomers). By 
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understanding the functional role of cetuximab, Jia et al. (2016) were able to predict and 
test a novel therapeutic use of cetuximab when combined with an allosteric inhibitor of 
EGFR, EAI045. Jia et al. (2016) observed that despite its high specificity to 
L858R/T790M mutant receptors, EAI045 was much less effective in cells than what was 
predicted in biochemical modeling. cetuximab/EAI045 combinatorial treatment 
effectively treated cellular and mouse models of lung cancer with either the 
L859R/T790M or L859R/T790M/C797S mutations that are typically resistant to 
cetuximab (Jia et al., 2016). Combinatorial therapy was successful because when a 
kinase pair is in the dimerized conformation, only the activator's allosteric site is 
exposed, whereas the allosteric site of the other kinase is oriented toward the interior of 
the dimer. Cetuximab prevented dimer formation, which exposed the allosteric sites in 
all receptors, thereby enhancing the efficacy of EAI045 (Jia et al., 2016). 
 
Cross-talk among kinases and activation of alternative pathways 
Redundancies in the activation of EGFR-mediated signal transduction pathways 
are a major source of resistance against EGFR-targeted therapies. There are several 
receptor families that can influence EGFR activity. G-protein coupled receptors 
(GPCRs) indirectly activate EGFR by encouraging release of EGFR ligands from their 
membrane bound states with the aid of metalloproteinases (Prenzel et al., 1999; 
Schneider & Wolf, 2009). The A disintegrin and metalloproteinase 17 (ADAM17) is 
often upregulated in human cases of colon cancer (Mustafi et al., 2017). Consequently, 
inhibition of ADAM17 suppresses EGFR activation and colon tumor formation in mouse 
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models (Mustafi et al., 2017). ADAM17 also activates ERBB2 and ERBB3 and its 
activity is linked to resistance to EGFR-TKIs. The estrogen receptor (ER), hepatocyte 
growth factor receptor (MET), and insulin growth factor receptor 1 (IGFR-1) have been 
shown to cross-talk with EGFR (Adams et al., 2004; Karamouzis et al., 2009; Skandalis 
et al., 2014), in which activation of one receptor promotes activity in the others. Colon 
cancer cells have been shown to utilize IGF-1-mediated cleavage of TGFα and 
subsequent upregulation of EGFR activity (Adams et al., 2004; Wang et al., 2002). 
Furthermore, IGFR-1, MET, and GPCRs (such as Angiotensin-II receptor type 1) can 
activate some of the same signal transduction pathways as EGFR by alternative means 
independent of EGFR phosphorylation. For instance, lung adenocarcinomas resistant to 
gefinitib often correlate with IGF-1 overexpression (Hurbin et al., 2011). Cross-talk also 
likely contributes to hyperactivity of effectors downstream of EGFR in tumorigenesis 
(such as ERK1/2, mTOR, AKT and STAT3), especially when there are no activating 
mutations in the EGFR gene. Cross-talk among downstream effectors (reviewed in 
Avraham & Yarden, 2011) further delineate outcomes.  
 Receptors with the EGFRvIII mutation can dimerize with wildtype EGFR when 
ligand is available. In the absence of ligand, EGFRvIII triggers recycling of the wildtype 
EGFR and switches to forming a complex with the MET receptor, allowing MET to 
become active (Li et al., 2015). Activated MET triggers pathways canonical to EGFR, 
such as PI3K/AKT and MEK/ERK. MET is also expressed in cells of epithelial origin, 
and its activity is a source of resistance to EGFR TKIs (Karamouzis et al., 2009). Given 
the tumorigenic properties of EGFRvIII-MET heterodimers, combinatorial therapy 
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targeting both EGFRvIII and MET has proven immensely beneficial in treatment of lung 
cancer and glioma in preclinical trials (Greenall et al., 2015; Greenall & Johns, 2016; 
Nakagawa et al., 2012). In large-scale clinical trials, combinatorial therapy for EGFRvIII 
and MET has had only modest effects or has been efficacious in a few properly designed 
clinical trials, but often with adverse toxicities such as diarrhea and skin rash (Solomon, 
2017). MET is rarely amplified in non-treated adenocarcinomas, meaning that it is 
through TKI selective pressure that its prominence arises (Siegelin & Borczuk, 2014). 
 Improved efficacy in combinatorial therapies can also be observed within the 
ERBB family. Takezawa et al. (2012) reported that ERBB2 amplification was found in 
12% of lung adenocarcinomas that were resistant to EGFR-targeted therapy. The 
occurrence of ERBB2 amplification was mutually exclusive to the T790M mutation 
(Takezawa et al., 2012). Combinatorial therapy with the EGFR inhibitor cetuximab and 
afatinib (which targets EGFR, ERBB2, and ERBB4) inhibited both receptors much more 
effectively than mono therapy, with a 40% response rate (Takezawa et al., 2012). 
 Downstream effectors of EGFR are often mutated in cancers, such as deleterious 
mutations in PTEN and upregulation of STAT3 activity in lung adenocarcinoma (Takata 
et al., 2012). Likewise, resistance to TKIs is often due to aberrant activity of downstream 
effectors. The PI3K/AKT pathway is particularly key to survival of cancer cells, due to 
its role in phosphorylating an abundance of downstream effectors and transcription 
factors that promote survival and proliferation. PTEN deleterious mutations are often 
found in cancers due to the role of PTEN in preventing phosphorylation of AKT. Given 
that hyperactive EGFR activity and loss of PTEN both serve similar roles in promoting 
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signal transduction, mutations in EGFR and PTEN tend to be mutually exclusive. When 
both mutations are found in the same tumor, such as in glioma EGFRvIII xenografts 
transduced with a PTEN loss-of-function mutation, a combination treatment with both 
EGFR and PI3K inhibitors was shown to suppress tumor growth (Fan & Weiss, 2010). 
KRAS is constitutively active in about 50% of colorectal cancer cases and is largely 
responsible for resistance to EGFR-targeted treatment due to its role in promoting AKT 
and ERK signaling. Mutations in KRAS are also a source of resistance against EGFR-
targeted therapies in NSCLC, accounting for 10% of resistant cases. In a worldwide 
study with 617 cases of NSCLC, KRAS mutations were not present in samples with 
EGFR activating mutations (Shigematsu et al., 2005). It is generally reported that EGFR 
and KRAS mutations are mutually exclusive, only rarely occurring within the same 
tumor. KRAS mutations occur most frequently among smokers, whereas EGFR 
mutations are more prevalent among nonsmokers, suggesting that different mutations are 
selected in different tissues, microenvironments, and in response to different 
environmental toxicants. Genetic mutations tend to be mutually exclusive when they 
share redundant physiological roles. EGFR, KRAS, and PTEN share the role of activating 
AKT and mutations in all three genes have been reported to be mutually exclusive to 
each other (Hosgood et al., 2013; Ikeda et al., 2000; Shigematsu et al., 2005). This 
suggests that generally there is little selective advantage to redundant mutations within 
the same pathway, at least in tumors that have not undergone selective pressure by 
targeted therapy. RAC is another downstream effector of EGFR that can become 
deregulated. In a heterogeneous breast cancer population consisting of both EGFR-
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sensitive and resistant cells, resistance was attributed to RAC hyperactivity. 
Combinatorial therapy with EGFR and RAC inhibitors reduced cell viability by 80% 
(Borrero-Garcia et al., 2017). 
 In vitro experiments with lung adenocarcinoma cells showed that even with 
EGFR inhibition, AKT pathway activity persists. Several other tyrosine kinase receptors, 
such as MET and IGFR-1, were shown to be active and involved in promoting AKT 
signaling (Shimamura et al., 2008). Interestingly, inhibition of heat shock protein 90 
(HSP90) effectively reduced phosphorylation of EGFR and other receptor tyrosine 
kinases, also suppressing downstream AKT activation and enhancing regression of 
adenocarcinomas in mice. This mode of treatment was effective even with mouse and 
cell models harboring the L858R mutation in conjunction with the T790M mutation 
(Shimamura et al., 2008). HSP90 may be involved in upstream activation of several 
tyrosine kinase receptors and has been shown to form a complex with EGFR, including 
the double mutant EGFR T790M/L858R. HSP90-targeted therapy might have two-fold 
benefits in inhibiting EGFR, by preventing HSP90 trans-activation of EGFR and by 
inadvertently targeting EGFR for degradation when the HSP90-EGFR complex is 
targeted (Ahsan et al., 2012; Sharma et al., 2007).  
 The best modes of treatment may be complex and multi-targeted, given the 
redundancies in the EGFR network that allow cells to adapt to specific treatments. For 
instance, compensatory PI3K upregulation has been observed when mTOR is inhibited. 
Currently, both are targeted to more effectively suppress the PI3K/AKT/mTOR pathway 
(Sharma et al., 2007). Several preclinical studies with breast cancer and glioma patients 
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have shown that combinatorial targeting of EGFR, PI3K, and mTOR are more effective 
at halting tumor progression than monotherapies (Fan & Weiss, 2010; Deng et al., 2015). 
However, apoptosis is not triggered and more effective outcomes are seen when the 
combination of inhibitors are used concurrently with other treatments that promote 
cytotoxicity (Fan & Weiss, 2010). 
 
Misregulated endocytosis of EGFR 
Inhibiting EGFR signaling is crucial to downstream signaling network activity. 
Mechanisms of EGFR signaling inhibition include dephosphorylation by tyrosine-
specific phosphatases, degradation, and recycling of the receptor. Endocytosis of 
dimerized ERBBs is triggered by a variety of stimuli and is mediated by several adaptor 
proteins. Internalized EGFR is either returned to the cell membrane or degraded by a 
ubiquitin-dependent mechansism, depending on an array of conditions. EGFR is able to 
remain active during this process (reviewed in Avraham & Yarden, 2011).  
 Cancer cells can maintain EGFR signaling by preventing dephosphorylation and 
degradation of the receptor. Avraham & Yarden (2011) noted that the tyrosine-specific 
phosphatase PTPRJ gene tends to have compromised function/mutations in carcinomas, 
likely due to its role in dephosphorylating EGFR. The Casitas B-lineage lymphoma 
proto-oncogene (CBL) is a commonly recruited ligase protein that is often misregulation 
in EGFR-dependent tumors due to its role in targeting EGFR for ubiquitination. For 
instance, mitogen-inducible gene 6 (MIG6) can acquire deleterious mutations in cancer 
and consequently interfere with CBL recruitment to EGFR, essentially preventing 
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ubiquitination of EGFR (Boopathy et al., 2018). In fact, MIG6-deficiency has been 
implicated in initiation and progression of various cancers, including incomplete 
degradation of mutant receptors harboring the exon 19 deletion or the L858R missense 
mutation (Ferby et al., 2006; Maity et al., 2015).  
There are multiple ways that EGFR internalization can be disrupted. For 
instance, the poxvirus has very low affinity to EGFR, but once bound, the virus keeps 
the receptor anchored to the cell membrane and prevents endocytosis of EGFR. The 
EGFR TKI Gefinitib has been shown to be effective in stopping the spread of poxvirus 
infection (Langhammer et al., 2011). It is interesting to note that poxvirus-based cancer 
therapies have had excellent clinical outcomes, due to preferential lysing of cancer cells 
and targeting them to elicit immune system responses (Sharp & Lattime, 2016). Cancer 
cells can also evade endocytosis of EGFR, such as in the case of the EGFRvIII mutation. 
EGFRvIII mutant receptors have low-level, prolonged signaling that evades 
internalization. The mutant receptor also evades ubiquitination by hypophosphorylation 
at the tyrosine 1045 residue which destabilizes binding to CBL, (Grandal et al., 2007; 
Zeineldin et al., 2010). 
Persistent EGFR signaling and crowding of receptors at the plasma membrane 
may also be due to endocytotic deregulation. Menard et al. (2018) showed that the 
balance between EGFR recycling and degradation is deregulated in cells with EGFR 
mutations, in favor of excessive receptor recycling and persistent signaling. Shifting the 
balance toward receptor degradation could be a potential route for future therapies. The 
clathrin-mediated EGFR recycling pathway is usually most active when EGF 
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concentrations are low (Sigismund et al., 2018), a likely mechanism to preserve a 
baseline of EGFR receptors at the plasma membrane. Inhibition of clathrin-mediated 
EGFR recycling induced EGFR degradation and apoptosis in cells with mutant EGFR, 
including TKI-resistant mutations such as T790M and C797S (Menard et al., 2018).  
 Ali & Wendt  (2017) postulated that transformation of tumors from primary to 
metastatic involves a switch from EGFR signaling dependency to suppression of EGFR 
transcription, non-canonical EGFR internalization signaling, and activation of other 
pathways that fulfill EGFR's growth-promoting functions, making these tumors 
inappropriate candidates for EGFR TKI treatment at the metastatic stages. This process 
is termed the EGFR paradox, in which EGFR agonist treatment at the metastatic stage 
triggers apoptosis of cancer cells, rather than promote growth (Ali & Wendt, 2017). 
 
Cardiac hypertrophy  
 The heart is abundantly studied because heart disease is the leading cause of 
death worldwide and is also the most common cause of death among cancer survivors 
due to chemotherapeutic-induced cardiotoxicities. The heart is a dynamic organ that can 
adapt to the body's physiological demands. Increased work demands can come from a 
variety of sources, some of which include exercise, hypertension, viral infections, and 
aortic valve abnormalities. Since cardiomyocytes are terminally differentiated cells that 
do not divide, the common mode of adaptation is through hypertrophy, in which 
cardiomyocytes increase in size by creating and organizing new sarcomeres, a process 
termed remodeling (Figure 1.2). The orientation of the sarcomeres depends on the type 
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of hypertrophy (concentric vs eccentric) and its underlying cause. For instance, aortic 
valve stenosis (such as in the case of calcification) can lead to the situation termed 
pressure overload, which is increased pressure that the heart must overcome when 
ejecting blood during systole. The heart can overcome this pressure overload by 
increasing the force of contraction, accomplished by thickening of the walls. In 
concentric hypertrophy, the sarcomeres are organized in parallel, expanding the 
thickness of the walls while not affecting the chamber diameter (Fernandes et al., 2011). 
Functionally, this can be detected by 2D echocardiography as increased diameters of 
walls along with increased ejection fraction (percent of blood ejected out of the left 
ventricular chamber during systole). In contrast, eccentric hypertrophy consists of 
sarcomeres created in series, so that the endocardium elongates in adaptation to an 
enlarged left ventricular (LV) chamber. In this situation, echocardiography would detect 
no change in wall thickness, but an enlargement of the LV chamber diameter and 
maintained ejection fraction (EF). Eccentric hypertrophy occurs as a consequence of 
volume overload, as is often the case when the aortic valve does not close properly after 
systole and there is regurgitation of blood back into the LV. This has a balloon-like 
effect in which the LV chamber expands to accommodate the extra volume. Eccentric 
hypertrophy can be a physiological response seen in endurance athletes whose hearts 
have to meet higher exercise demands, whereas concentric hypertrophy occurs with 
strength training (Fernandes et al., 2011). Eccentric hypertrophy, hypertrophic 
remodeling, and concentric hypertrophy can all occur in pathological cases. In addition, 
the heart can switch between the different types of hypertrophy as a response to changes 
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in work demand. With time, the initial mode of adaptation can further diminish the 
capabilities of the heart to maintain cardiac output, leading to continuous changes in 
sarcomere structure. 
 Eccentric hypertrophy has the propensity to become dilated cardiomyopathy, in 
which contractility is compromised due to the large LV volume that needs to be ejected 
at systole. At this stage, echocardiography can detect reduced contractility (decrease in 
EF). This is the most widely used diagnostic parameter in detecting cardiomyopathy and 
heart failure. While wall thickening and LV dilation are adaptive responses to pressure 
or volume overload that may accumulate with age, continually increased cardiac mass is 
linked to mortality and morbidity and leads to compromised contractile function. As the 
heart increases in mass due to hypertrophy, there is greater energy demand placed on 
cardiomyocytes that cannot be met, placing cardiomyocytes at risk of apoptosis. Since 
cardiomyocytes cannot divide, apoptotic cells are replaced by fibrotic or necrotic tissue. 
Hearts with fibrosis/collagen replacement of cells, have compromised function and are a 
hallmark of cardiomyopathies and heart failure.  
 
EGFR signaling pathways involved in cardiomyopathies 
 EGFR's role in heart physiology is not yet well-defined, but several studies have 
begun revealing cardiovascular consequences of misregulated EGFR signaling. 
Abundant data has shown that the ERBB family and their ligands are required for 
cardiac development (reviewed in Makki  et al., 2013). EGFR-deficient mice in 
particular develop aortic valve defects as well as genetic background-dependent 
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hypertrophic remodeling (Barrick et al., 2009). Studies on ERBB signaling in the heart 
have historically focused on ERBB2 and ERBB4. This is likely due to the fact that 
ERBB2 and ERBB4 are more abundantly expressed in cardiomyocytes than EGFR. 
However, function is often more relevant than expression level in revealing the 
relevance of a protein, since many enzymes have been shown to be highly effective at 
low expression levels. It is also possible for EGFR expression levels to fluctuate in a 
stimulus-dependent manner - a topic, that to our knowledge, has not been studied.  
 Cardiotoxicity studies have focused more on ERBB2 because pharmacological 
inhibition of ERBB2 is associated with severe cardiotoxicity and heart failure in 10-28% 
of breast cancer patients, often associated with pre-existing heart conditions (Martin et 
al., 2009; Wadhwa et al., 2009; Zeglinski et al., 2011). Trastuzumab, an ERBB2 
inhibitor, has been shown to suppress activity of intracellular signaling pathways 
essential for cardiomyocyte survival such as MAPK/ERK and PI3K/AKT, pathways 
which are downstream of the ERBB receptors (De Keulenaer et al., 2010). Even though 
these signal transduction pathways are also regulated by EGFR, much less is known 
about cardiotoxicity rates of EGFR inhibitors and more generally, of EGFR's role in the 
cardiovascular system. EGFR-specific TKIs are generally considered to be of low 
cardiotoxicity risk, with few reports in the literature showing adverse effects (Grisanti et 
al., 2015). In one such study, Barrick et al. (2008) demonstrated that after 3 months of 
EGFR TKI treatment, C57BL/6J mice had a higher incidence of apoptotic cells in the 
left ventricle, thinning of the left ventricular walls and dilation of the chamber, and 
exacerbated calcification of the aortic valve. 
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 The Angiotensin II type 1 receptor (AT1R) is a key GPCR in the cardiovascular 
system that has been well-studied (Belmonte & Blaxall, 2012). Deregulation of AT1R 
signaling, especially by high levels of Angiotensin-II (Ang-II), is implicated in several 
heart diseases including cardiomyopathy. EGFR is trans-activated via two Ang-II-
mediated mechanisms. One method is via Ang-II-mediated activation of SRC, which 
then phosphorylates the cytoplasmic domain of EGFR. A second method is Ang-II-
mediated cleavage of HB-EGF via the metalloproteinase ADAM17, reported in vascular 
smooth muscle cells and cardiac fibroblasts (Chen, 2006; Makki et al., 2013). Blocking 
of this trans-activation mechanism with an ADAM17 inhibitor was shown to attenuate 
left ventricular hypertrophy even in the presence of Ang-II infusion, demonstrating that 
EGFR is the conduit for Ang-II-mediated hypertrophy (Asakura et al., 2002). This 
conclusion has been supported by several experiments (Paradis et al., 2000; Peng et al., 
2016; Thomas et al., 2002), including the use of the EGFR TKIs for reducing incidence 
of Ang-II induced hypertrophy (Peng et al., 2016). Studies have shown that mice 
exposed to EGFR antisense oligonucleotides have lower incidence of developing 
Angiotensin II-induced hypertrophy (Kagiyama et al., 2002). These experiments 
demonstrate that EGFR stimulation is sufficient to induce cardiac hypertrophy, 
suggesting a functional role for EGFR in the heart's adaptation to stimuli.  Kagiyama et 
al. (2002) demonstrated that Ang-II-mediated trans-activation of EGFR leads to 
activation of the MEK/ERK pathway, which several studies have shown directly impacts 
the occurrence of cardiac hypertrophy (De Pasquale et al., 2018). For instance, 
Neurofibromin (which deactivates RAS) knock-out mice have hyperactivity of the 
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RAS/RAF/MEK/ERK pathway with increased incidence of hypertrophy and 
cardiomyopathy (Xu et al., 2009). 
 The literature is undecided on the exact function of ERK in cardiac hypertrophy, 
with some studies reporting that ERK activity promotes hypertrophy and others 
demonstrating that inhibition of ERK also contributes to hypertrophy. The explanation 
for such contrasting results may be that ERK functions as a switch between two types of 
hypertrophy (Kehat et al., 2011). ERK has been shown to be involved in promoting a 
concentric hypertrophic response, especially to pressure overload, although it is not the 
only pathway necessary for this (Bernardo et al., 2010; Mutlak & Kehat, 2015). In 
addition to promoting an adaptive concentric hypertrophic response, ERK is critical for 
protection against eccentric hypertrophy, as demonstrated with ERK1/2-deficient mice 
(Kehat et al., 2011; Mutlak & Kehat, 2015). EGFR is a likely upstream mediator of the 
ERK hypertrophic response, given that EGFR knockout mice have been shown to have 
lower blood pressure and increased incidence of severe eccentric hypertrophy and that 
rats treated with the EGFR inhibitor AG1478 had impaired cardiac function and early 
indications of eccentric hypertrophy (Schreier et al., 2013).  
 Both ERK and EGFR are often highly expressed in cases of dilated 
cardiomyopathy, as well as in heart failure (Haq et al., 2001). The necessity of ERK to 
prevent eccentric hypertrophy and the abundance of ERK expression in dilated 
cardiomyopathy seem to be opposing observations. There are several possible 
explanations for the emergence of ERK overexpression in dilated cardiomyopathy 
(DCM). The first hypothesis is that ERK may be upregulated to suppress existing 
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eccentric hypertrophy, but this may be a futile effort once progression to dilated 
cardiomyopathy has already commenced. The second potential explanation is that the 
function of ERK may switch in a sort of paradox, in which ERK activity initially 
suppresses eccentric hypertrophy but after dilated cardiomyopathy is established, ERK 
activation may serve a different function. Experiments that inhibit ERK within a dilated 
cardiomyopathy mouse model would help in determining which is the most likely 
explanation of why ERK is upregulated in cases of DCM. For instance, if ERK 
inhibition has no effect on or worsens DCM, then upregulation of ERK may function as 
a minimally effective mechanism to suppress DCM.  If instead ERK inhibition reduces 
severity of DCM, then the results would support the paradox explanation. Results from 
our group demonstrate that BALB/cJ mice, a strain prone to developing DCM, treated 
with the EGFR TKI AG1478 developed more severe hypertrophy than untreated mice 
(Howe et al., unpublished), supporting the first explanation and suggesting that EGFR-
mediated ERK activity may play a role in suppressing DCM. 
Many studies have correlated upregulated AKT activity with cardiac hypertrophy 
and there is a general consensus that short-term AKT phosphorylation is involved in 
physiological cardiac hypertrophy (associated with improved cardiac function) whereas 
long-term AKT activity is associated with pathological cardiac hypertrophy (Kemi et al., 
2008; Matsui et al., Nagoshi, 2003; Shiojima & Walsh, 2006; Shiojima et al., 2002). 
There are numerous combinations of initiating stimuli (including exercise, hypertension, 
aortic valve stenosis), membrane receptors, and downstream feedback loops that 
contribute to the large range of outcomes reported in the AKT signaling pathway 
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(Adams et al., 1998; Arkun, 2016; Bernardo et al., 2010; Condorelli et al., 2002; 
DeBosch et al., 2006; DeBosch et al., 2006; Dent, 2014; Dorn & Force, 2005; Ikeda et 
al., 2015; Pillai et al., 2014; Sakata et al., 1998; Sundaresan et al., 2012). EGFR can 
trigger activation of the PI3K/AKT/mTOR pathway, thus promoting cardiomyocyte 
survival and preventing fibrosis. For example, Gαq expression was shown to protect 
cardiomyocytes against apoptosis while also promoting pressure overload-induced 
hypertrophy (Adams et al., 1998; Howes et al., 2006; Sakata et al., 1998). Howes et al. 
(2006) demonstrated that the anti-apoptotic properties of Gαq were due to EGFR-
mediated AKT activity, which was protective against apoptosis in cardiomyocytes 
cultured with 2-deoxyglucose. Treatment with inhibitors that targeted either EGFR or 
the upstream mediator, SRC, removed the protective effects (Howes et al., 2006). These 
experiments, taken together with in vivo findings by Barrick et al. (2008) showing that 
EGFR TKI treatment promoted apoptosis within the left ventricle, signal that there are 
potential adverse consequences to cardiomyocyte survival when inhibiting EGFR.  
While EGFR and AKT were necessary for cell survival, inhibition of either 
kinase had no impact on cardiac hypertrophy (Howes et al., 2006), indicating that Gαq-
mediated hypertrophy occurred in an EGFR and AKT-independent manner. Although 
EGFR is not required to induce hypertrophy in these scenarios, the 
EGFR/Ras/Raf/MEK/ERK signaling pathway may still play a key role in regulating 
AKT activity. For instance, ERK was shown to activate mTOR in rat cardiomyocytes in 
an AKT-independent manner (Martin et al., 2001; Sato et al., 2014; Wang et al., 2001). 
Carriere et al. (2010) demonstrated that ERK was able to directly phosphorylate mTOR-
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bound raptor. Other experiments have shown that ERK can also phosphorylate GAB1 
and thus prevent GAB1-mediated recruitment of PI3K to EGFR (Yu et al., 2002), 
essentially inhibiting the AKT pathway. ERK-mediated inhibition of AKT is also 
reported in insulin resistant diabetes, which can be relieved by treatment with ERK 
inhibitors (Ozaki et al., 2016). There is the caveat that EGFR may not always be 
necessary in mediating ERK, as IGFR-1 can also activate RAS and initiate the 
RAS/RAF/MEK/ERK cascade. Taken together, AKT activity is associated with cardiac 
hypertrophy (both concentric and eccentric depending on the stimuli and agonists 
involved), and ERK plays a role in cross-inhibiting the AKT pathway. We postulate that 
when ERK is inhibited, as in the case of ERK1/2 knockout mice or more indirectly with 
mice exposed to pharmacological inhibitors of EGFR (Kehat et al., 2011; Howe et al., 
unpublished), ERK-mediated inhibition of AKT is removed, which effectively activates 
the AKT pathway and permits subsequent eccentric hypertrophy. In a study with EGFR 
knockout mice, Schreier et al. (2013) reported increased incidence of eccentric 
hypertrophy as well as NADPH-oxidase 4 (Nox4) levels. NADPH-oxidase is an 
upstream regulator of Ang-II-mediated AKT activation and is important to Ang-II 
induced hypertrophy (Hingtgen et al., 2006). AKT/mTOR has been shown to be the 
conduit for Nox4-mediated hypertrophy (Zhao et al., 2015) and many studies have 
implicated EGFR in Ang-II-mediated hypertrophy as well (Asakura et al., 2002; Paradis 
et al., 2000; Peng et al., 2016; Thomas et al., 2002). Studies have shown that not only 
does Nox4 activate AKT, but it also triggers SRC-mediated activation of internalized 
EGFR as well as subsequent ERK activation (Gorin & Block, 2013; Kim et al., 2017; 
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Truong & Carroll, 2012; Zhang et al., 2014). It is possible that loss of EGFR would 
disrupt ERK-AKT crosstalk, resulting in hyperactivity of the AKT pathway, increased 
hypertrophy, and increased levels of NOX4 in compensation for the absence of EGFR. 
Increased oxidative stress in response to EGFR inhibition was also reported in studies 
that treated rats with AG1478 (Mak et al., 2015; Weglicki et al., 2012). Reduced systolic 
and diastolic functions as well as early stages of dilated cardiomyopathy were observed, 
and the authors concluded that the cardiac changes were a consequence of oxidative 
stress induced by hypomagnesemia, given that EGFR activity promotes the magnesium 
channel transient receptor potential melastatin 6 (TRPM6). 
 
EGFR genetic modifiers  
Modifier genes are key to the prediction of individual disease risk and response 
to treatment. The existence of genetic modifiers is most evident when individuals 
carrying the same mutation have different phenotypic and disease outcomes. For 
example, EGFR-null mouse embryos have been shown to have a range of outcomes, 
from lethality during gestation to robust survival to term. Their survival depended 
largely on genetic background-mediated modification of EGFR’s role in the developing 
placentae (Dackor et al., 2007). In human oncology, SNPs associated with expression of 
EGFR, as well as a nearby gene encoding a GPCR, were found to modify progression 
free survival among adenocarcinoma patients treated with EGFR TKIs (Chang et al., 
2016). Another study identified 18 genes (including some from the SRC family) 
involved in determining the degree of dependency that NSCLC cells may have on the 
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EGFR activating mutations that they harbor, i.e. predict how effective EGFR TKI 
treatment would be on these cells based on how dependent they are on their EGFR 
mutation (Sharifnia et al., 2014). There is currently an ongoing Genome-Wide 
Association Study that aims to identify genetic modifiers that determine EGFR TKI 
treatment outcome (NCT01838577). The high incidence of EGFR mutations found 
among NSCLC patients of Southeast Asian ethnicity may indicate the presence of 
genetic modifier polymorphisms that are more permissive to the development of 
adenocarcinomas carrying EGFR mutations (Sellers & Meyerson, 2005), although the 
influence of polymorphisms within EGFR must be considered when determining 
influences from genetic modifiers. Overall, modifiers genes determine the availability 
and roles of target genes and gene products, thereby contributing to genetic interactions 
within a network and ultimately influencing cellular decisions. Utilizing a single mouse 
strain when studying complex diseases, such as cardiomyopathies and cancers, restricts 
interpretations of experimental findings, as a single inbred mouse strain only represents 
one possible combination of modifier alleles. 
 
Specificity of EGFR inhibitors 
 Although EGFR inhibitors are designed to have high specificity for EGFR, the 
possibility remains that these inhibitors also bind to other tyrosine kinases and 
consequently contribute to off-target side effects. Potential cardiotoxicity effects, for 
example, may be due to a generalized tyrosine kinase inhibition rather than EGFR 
inhibition alone. It is generally accepted that compounds that have high affinity to their 
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target are intrinsically of high specificity as well. AG1478 for example, has an affinity 
for EGFR of IC50 = 3 nM, where 100 uM is the minimum concentration required for 
non-specific binding to ERBB2 and PDGF (Osherov & Levitski, 1994). However, the in 
vivo outcomes of physiologically-relevant doses of AG1478 likely yield different 
specificity results than what is typically tested in a cell culture system. The use of a 
genetic model of EGFR inhibition, such as the combination of the hypomorphic 
EGFRwa2 variant with an inducible EGFR knockout allele, would help clarify whether 




 The EGFR signaling network is essential for cell survival and metabolism. 
Hence, there is much redundancy in activation of EGFR and its downstream pathways, 
allowing the network to adapt in response to perturbations. More advanced stages of 
cancer require combinatorial therapies that inhibit growth-promoting networks through 
targeting of multiple factors. This is due to the inherent heterogeneity observed in late 
stage tumors. In this review, we hope to have conveyed that there is a large amount of 
redundancy in signaling networks and therefore numerous ways for a heterogenous cell 
population to escape targeted therapies.  
 Current methods of anti-cancer targeted treatment can be of limited scope, often 
generating selective pressure for specific mutations in a population and/or triggering 
adaptation by the EGFR network, ultimately conferring resistance to treatment (Figure 
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1.3). Understanding the interactions and limitations of EGFR's signaling network is 
crucial to correcting signal imbalances common to human diseases. Treatments that 
target mechanisms that are more generally utilized by cancer cells, such as favoring 
EGFR degradation by inhibiting receptor recycling (Menard et al., 2018), may become 
more popular as more is understood about how EGFR is misregulated in cancer. Cancer 
can be viewed as an evolutionary process that is sensitive to selective pressures within 
its microenvironment, including pressures from targeted treatments, requiring re-
evaluation of patients throughout the treatment process. Interestingly, selective pressures 
sometimes work in favor of treatment, such as when TKI-treated NSCLC transforms into 
the much more treatable small cell carcinoma. This begs the question of whether 
artificial selection, such as manipulation of the microenvironment, can be used to drive 
the cell population toward a more treatable outcome. 
 Early stage cancers are much more homogenous and responsive to treatment, 
with fewer rogue cells able to acquire a selective advantage after exposure to treatment. 
Taken together, early detection and preventative treatment are of extreme importance in 
avoiding tumor heterogeneity. Tang et al. (2005) examined samples of lung 
adenocarcinomas with EGFR mutations and found that 43% of the patients also had 
EGFR mutations in normal lung epithelium. The authors concluded that EGFR 
mutations are present at the early stage of tumorigenesis and that EGFR might be a good 
target for chemoprevention. Overall, early detection and prevention could be immensely 
beneficial since cancer cells would have a smaller chance to acquire new mutations and 
undergo selection by bottleneck or selective pressures. 
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 With EGFR-targeted therapies becoming more common there is an increased 
need to understand how genetic background confers resistance to treatment and 
susceptibility to toxicities. Cardiotoxicity resulting from ERBB2-targeted treatment is 
much more widely observed than with EGFR-targeted therapies. A possible explanation 
is that ERBB2 may be essential for maintenance of cardiomyocytes, whereas EGFR may 
be more important for response to stress. Therefore, inhibition of EGFR may have 
adverse consequences on the heart during times when the heart is undergoing 
compensatory changes. Individuals at risk for therapy resistance and toxicity are more 
likely to be identified through the use of comprehensive preclinical models 
encompassing both genetic diversity and sensitive assays that detect cardiotoxicity. The 
fact that inhibition of either EGFR or ERK promotes eccentric hypertrophy highlights 
the significance of targeting cancer cells specifically while avoiding off-target cells such 
as cardiomyocytes. Many advancements have been made since the discovery of EGFR 
and early trials with targeted treatment, yet there is much still to learn on how genetic 
networks cross-talk, how cancer cell populations evolve, and how allelic differences 











Figure 1.1. Diagram of EGFR protein. EGFR in the following configurations: (a) 

















Figure 1.2. Diagram of cardiac concentric and eccentric hypertrophies. Concentric 
hypertrophy is characterized by the orientation of sarcomeres in parallel, resulting in 
thickened left ventricular walls. In eccentric hypertrophy, the sarcomeres are arranged in 






















Figure 1.3. Adaptation of a cancer cell population to targeted treatment. (a) A 
mutation arises, which (b) promotes proliferation of mutant cells. (b-c) One cell acquires 
an additional mutation that further enhances proliferation. (d) Targeted treatment 
commences to target the rapidly expanding red and blue cells in an increasingly 
heterozygous population. (e) Treatment eliminates the target cells, but cells resistant to 
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CHAPTER II  
INHIBITION OF EGFR BY AG1478 AUGMENTS HYPERTROPHY IN AGED 
BALB/CJ MICE WITH DILATED CARDIOMYOPATHY 
 
Introduction  
The epidermal growth factor receptor (EGFR) is a member of the ERBB family 
of receptor tyrosine kinases, consisting of EGFR/HER1, ERBB2/HER2, ERBB3/HER3, 
and ERBB4/HER4. The ERBB receptors are broadly expressed during embryonic 
development, normal adult physiology, and cancer progression due to their pivotal roles 
in promoting cell proliferation, differentiation, survival, and migration. EGFR is often 
co-opted by cancer cells through up-regulation of the receptor’s expression and/or 
activity, even in the absence of activating mutations in the EGFR gene (Chakraborty et 
al., 2014; Gan et al., 2013; Khambata-Ford et al., 2007; Kobayashi & Mitsudomi, 2016; 
Maretzky et al., 2011; Schiff et al., 2004; Siegelin & Borczuk, 2014). The prevalence of 
aberrant EGFR activity in human cancers has made EGFR-targeted mono or 
combinatorial therapies common strategies for inhibiting tumor growth (Wang et al., 
2018). EGFR antibodies that bind EGFR's ligand-binding domain (for example, 
panitumumab and cetuximab) as well as small molecule inhibitors (such as gefinitib and 
erlotinib), which compete with ATP for binding sites on EGFR's kinase domain, are 
used clinically to treat a variety of cancers including breast, pancreatic, non-small cell 
lung carcinoma, colorectal and head and neck cancers (Hervent & De Keulenaer, 2012; 
Kobayashi & Mitsudomi, 2016).  
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Heart disease is the leading cause of death worldwide and is also the most 
common cause of death among cancer survivors due to chemotherapeutic-induced 
cardiotoxicities. For instance, studies have shown that an alarming number of adults who 
survived cancer during childhood may still have long-lasting cardiotoxic effects years 
later (Lipshultz et al., 2015). The most common side effects of EGFR-targeted therapy 
are skin rashes, follicular damage to hair, hypomagnesemia, and diarrhea (Fakih et al., 
2006; Li & Perez-Soler, 2009; Solomon, 2017; Weglicki et al., 2012). Interstitial lung 
disease is a less common (with about 1% incidence) but severe adverse effect of 
treatment (Inoue et al., 2003; Qi et al., 2015). To our knowledge, there are no reports in 
the literature showing cardiotoxicity effects caused directly by EGFR inhibition, apart 
from previous studies from our group (Barrick et al., 2009; Barrick et al., 2008). Barrick 
et al. (2008) demonstrated that C57BL/6J adult mice treated with either the EGFR small 
molecular inhibitor EKB-569 or AG1478, for three months had adverse cardiac changes, 
involving left ventricular apoptosis, wall thinning, left ventricular dilation, and an 
exacerbation of the mouse strain's tendency toward aortic valve calcification. These 
studies have shown serious implications of potential adverse consequences to EGFR-
targeted therapies. Any potential cardiotoxicity rates for EGFR-targeted therapies are 
unknown and likely missed due to insufficient clinical modeling and understanding of 
EGFR's role in the heart. De Keulenaer (2012) and others have stressed that the 
functional role of EGFR in the cardiovascular system is of greater importance than 
EGFR's expression levels when trying to predict cardiotoxicity outcome.   
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The ERBB2 receptor, which is more abundantly expressed in cardiac tissue than 
EGFR, is upregulated in about one-third of breast cancer cases (Mendelsohn, 2002). 
There is a plethora of evidence from ERBB2-positive breast cancer studies showing 
adverse cardiac effects caused by treatment with the ERBB2 antibody trastuzumab 
(Martin et al., 2009; Wadhwa et al., 2009; Zeglinski et al., 2011). Trastuzumab has been 
shown to suppress activity of intracellular signaling pathways essential for 
cardiomyocyte survival such as MAPK/ERK and PI3K/AKT, pathways which are 
downstream of the ERBB receptors (De Keulenaer et al., 2010). An estimated 10-28% of 
ERBB2-positive breast cancer patients are at increased cardiotoxicity risk, partly due to 
pre-existing heart conditions. Despite the fact that the MAPK/ERK and PI3K/AKT 
signaling pathways are also regulated by EGFR, far less is known on the cardiac side 
effects of EGFR inhibitors or more generally of EGFR's role in the cardiovascular 
system. There may be unidentified groups at risk for adverse cardiac effects when 
undergoing EGFR-targeted therapy. 
One hypothesis is that any cardiotoxic effects of EGFR inhibition may be due to 
impaired ERBB2 signaling, since ERBB2 is the preferred binding partner for activated 
EGFR. However, EGFR has specifically been shown to play a critical role in the 
development of cardiac hypertrophy. While ERBB2 is essential for cardiomyocyte 
maintenance and survival, accumulating evidence supports the hypothesis that EGFR is 
an important regulator of cardiac remodeling during times of adaptive change. 
Angtiotensin-II (Ang-II) receptor hyperactivity has long been linked to cardiac 
hypertrophy among other conditions. The likely mechanism for Ang-II-induced 
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hypertrophy is transactivation of EGFR (Kagiyama et al., 2002). Inhibition of EGFR by 
either blocking Ang-II-induced transactivation or by the small molecule inhibitor of 
EGFR, AG1478, was sufficient to prevent Ang-II induced hypertrophy (Paradis et al., 
2000; Peng et al., 2016). Studies have implicated upregulation of ERK activity in the 
process of promoting adaptive concentric hypertrophy and in suppressing eccentric 
hypertrophy and dysfunction (Kehat et al., 2011; Mutlak & Kehat, 2015). Taken 
together, the upregulation of EGFR and ERK during adaptive cardiac remodeling 
suggests that EGFR has an adaptive mediator function. From this, we can hypothesize 
that inhibition of EGFR would impair the ability of the heart to cope with stress, 
particularly with stress that promotes eccentric hypertrophy.   
 There is a need to understand individual response to targeted therapy for the 
purpose of toxicity avoidance. In the present study, we evaluated the spectrum of 
cardiotoxicity responses to EGFR inhibition using four genetically distinct mouse strains 
(A/J, BALB/cJ, C57BL/6J, FVB/NJ) treated with varying sub-therapeutic to therapeutic 
doses (0, 5, 50 and 144 mg/kg) of AG1478 for 16 months. We chose subtherapeutic 
doses for the purposes of low dose cancer prevention based on previous research in 
which inhibition of EGFR reduced tumor load in mouse models of colorectal cancer 
(Rinella & Threadgill, 2012; Roberts et al., 2002; Torrance et al., 2000), whereas 144 
mg/kg is a clinically-relevant therapeutic level dose. EGFR activity has been shown to 
be a requirement for Western diet-induced development of colon cancer in mouse 
models (Dougherty et al., 2008; Fichera et al., 2007; Mustafi et al., 2017). To more 
realistically model the Western diet lifestyle and health risks, AG1478 was incorporated 
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into a Western Diet mouse chow (high fat, high sugar), which has been demonstrated to 
be an effective mode of administering the drug (Barrick et al., 2008). Recently, EGFR’s 
downstream effector, ERK, has been implicated in metastatic prostate cancer under a 
high fat diet influence, demonstrating the importance of metabolic changes induced by 
diet (Chen et al., 2018). We monitored cardiac changes in vivo throughout the 16 months 
of treatment by 2D echocardiography (M-mode, speckle tracking, and tissue doppler), 
with the goal of assessing whether long-term EGFR inhibition has adverse 
cardiovascular outcomes. Heart and spleen tissues were analyzed by histopathology to 
further evaluate cardiotoxicity-related changes and to investigate whether genetic 
background-dependent immune responses contributed to instances of decompensated 
eccentric hypertrophy.  
 
Materials and Methods 
Animals and Husbandry 
We obtained mice that were 6-to-8-weeks-old (A/J, BALB/cJ, C57BL/6J, and 
FVB/NJ strains) from The Jackson Laboratory (Bar Harbor, ME). There were 160 mice 
per strain, 80 males and 80 females, to equal a total of 640 animals on study. Baseline 
measurements were taken after one week of acclimation to the facility and treatment 
commenced at ages 8-10 weeks. Animals were measured for all parameters at 4-month 
intervals, yielding a total of 5 time points (0, 4, 8, 12, and 16 months), with some time 
points omitted for particular parameters as noted in the corresponding sub-methods 
sections. The mice were housed 5 per cage, in Nextgen filtered cages, at 22° C under a 
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12-hour light/dark cycle. In all our experiments, we adhered to Animal Use Protocols 
approved by the Texas A&M University Institution Animal Care and Use Committee. 
Mice were euthanized by carbon dioxide asphyxiation and immediately necropsied. 
Tissues were either flash frozen in liquid nitrogen or fixed in formalin.  
 
Diet and Delivery of AG1478 
Tryptosin AG-1478 was purchased from LC Laboratories (Woburn, MA) and 
incorporated into Western Diet mouse chow (D12079B) by Research Diets, Inc. (New 
Brunswick, NJ). The therapeutic-level dose chosen was 144 mg of AG1478/kg of food, 
shown to be sufficient to inhibit EGFR phosphorylation (Barrick et al., 2008; Rinella & 
Threadgill, 2012). The 50 mg/kg sub-therapeutic dose was selected due to its efficacy at 
inhibiting cancer cell growth at an equivalent dose in vitro (Lee et al., 2005), with the 
lowest dose chosen to be 1/10th of the 50 mg/kg dose (i.e. 5mg/kg). The control chow (0 
mg/kg) consisted of the Western diet alone. Food dyes were added for ease of feeding 
purposes, and mice received food and water ad libitum.  
 
Food consumption 
 Mice were singly-housed in Phenomaster Metabolic cages (TSE Systems, 
Chesterfield, MO) for 48 hours. Data collected during the first 24 hours were used as an 
acclimation period and were thus omitted from analysis. Food and water consumption 
were measured by the system's weighing sensors that attached to feeding and drinking 
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dispensers. Mice that drank less than 0.5 mL within the first 24-hour period were 
omitted from analysis. 
Echocardiography 
 Animals were prepared for the procedure the previous day by removal of chest 
hair with a depilatory cream under 4% anesthesia. 2D echocardiography images were 
acquired with the Vevo 3100 Preclinical Imaging System (VisualSonics/FujiFilm, 
Toronto, ON). The mice were scanned un-anesthetized with a 40 MHz transducer 
(MX550D). 2-dimensional video loops were collected for M-mode, B-mode, and PW 
Tissue Doppler. Long axis and parasternal short axis images were acquired at the level 
of the papillary muscles under the B and M-mode settings. Long axis B-mode and short 
axis M-mode videos were recorded for all 5 time points (0, 4, 8, 12, and 16 months on 
diet). Long and short axis B-mode images were analyzed with the VevoStrain package, 
allowing for quantification of myocardial deformation, although the short axis B-mode 
videos were acquired only for the 8, 12 and 16-month time points. PW Tissue Doppler 
images were obtained only for the 12 and 16-month time points. Images were traced on 
the VevoLab software by two independent and blinded observers and the values from 
both observers were averaged for each animal. Among the parameters obtained were left 
ventricular anterior and posterior wall thicknesses, left ventricular internal diameter, 
stroke volume, fractional shortening, cardiac output, heart rate, mitral E'/A' ratio, 
longitudinal strain, circumferential strain, and radial strain. Given the complex 
interactions among variables and the non-normality nature of the data distribution, 






 Values for fat and lean masses, measured in grams, were obtained using the 
EchoMRI-100H body composition analyzer (EchoMRI, Houston, TX). 
 
Histopathology 
 At necropsy, hearts were cut at necropsy with a scalpel, with an initial transverse 
cut at the apex followed by a longitudinal cut toward the cranial end. The sections 
obtained for histology (the apex piece and half of the cranial end piece) were fixed in 
formalin for 48 hours, then stored in 70% ethanol until processed and paraffin 
embedded. Five μm sections were obtained at the plane of the papillary muscles and 
stained with hematoxylin and eosin. Spleens were fixed and processed as whole tissues 




Heart tissues were homogenized at 4º C using the TissueLyser II (Qiagen, 
Hilden, Germany). For the RNA extraction, we utilized the E.Z.N.A. Total RNA Kit I 
(Omega Bio-Tek, Norcross, GA) and added an incubation step with TRIzol (Invitrogen, 
Waltham, MA). The Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, 
Risch-Rotkreuz, Switzerland) was used to set up the reverse transcription reaction. The 
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Timp1 and Spp1 primers were obtained from (Sigma-Aldrich, St. Louis, MO). The 
sequence for the sense and anti-sense primers for Timp1 were: 
CATCCTCTTGTTGCTATCAC and CATGAATTTAGCCCTTATGACC, respectively. 
The primers for Spp1 were: GGATGAATCTGACGAATCTC and 
GCATCAGGATACTGTTCATC. The qPCR reaction was performed on the LightCycler 
96 System with 480 SyBr Green 1 Master (Roche Diagnostics, Risch-Rotkreuz, 
Switzerland). cDNA was diluted at 1:5. Primers were used at a concentration of 10uM 
and had efficiencies close to 100% (with ∆CT scores near 3.3). Timp1 and Spp1 
expression were normalized to the average of β-actin, Gapdh and Hprt. Fold differences 
were calculated by the 2^(∆∆CT) formula. 
 
Results  
Genetic background-dependent differences in baseline echocardiographic parameters.  
 During baseline echocardiographic measurements, we observed consistent 
differences between mouse strains (Figure 2.1; Table 2.1) that can be separated into two 
groups that had some major distinctions. The A and BALB strains have larger left 
ventricular internal diameters (LVID) than the B6 and FVB group. The A and BALB 
strains also had higher cardiac output (CO) and stroke volume (SV). In contrast, the B6 
and FVB group had greater left ventricular mass (LVM) than the A and BALB mice. 
Correspondingly, the B6 and FVB mice also had thicker left ventricular anterior and 
posterior walls (LVAW and LVPW). A key difference between the B6 and FVB strains 
is that FVB mice have greater LVM, LVAW, and LVPW than the B6 mice. Likewise, a 
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difference between the A and BALB strains is that the A mice had a slightly thicker 
LVAW and the BALB had a larger LVID. These genetic background-dependent patterns 
were consistent for both male and female mice (Table 2.1).  
 
Age-related cardiovascular changes vary by genetic background. 
 In order to evaluate the presence of cardiotoxicity, we first had to understand 
which changes occurred naturally due to aging (Figure 2.2). We compared trends over 
time among control mice and separated the trends by strain but not sex, since there were 
significant baseline differences in cardiac structure between mouse strains but no 
differences in overall trends between sexes within each strain (Tables 2.2-2.5). All 
genetic backgrounds had increased left ventricular mass (LVM) by the 16th month time 
point, compared to corresponding baseline LVM (Figure 2.2; Figures 2.3-2.6). The 
magnitude of the trends was different for each mouse strain, with the BALB and B6 
mice having greater increases in LVM than the A and FVB mice. LVID followed similar 
trends, with one distinct difference in that LVID did not change for the FVB/NJ mice. 
Some consequences of these structural changes were that CO and SV increased the most 
for the mice with the greatest increases in LVM and LVID (BALB and B6). CO and SV 
increased only slightly for the A mouse strain, which had only minor increases in LVM 
and LVID in comparison to BALB and B6. Although the FVB mouse strain also had a 
minor increase in LVM, the lack of change in LVID corresponded to a slight decrease in 
CO and SV. All genetic backgrounds had notable increases in left ventricular anterior 
wall (LVAW) thickness, with A mice having a smaller change in magnitude than the 
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other mouse strains, which had a similar amount of change in LVAW relative to each 
other. There were genetic background-dependent trends in left ventricular posterior wall 
(LVPW) thickness. FVB and A mouse strains had an increase in LVPW thickness that 
was equivalent to the degree of change in LVAW, resulting in a uniform increase in 
overall LV wall thickness. The BALB and B6 mice had a non-uniform LV wall 
thickness, with little to no change in LVPW despite the increased LVAW thickness. 
 
The BALB/cJ genetic background is predisposed toward developing dilated 
cardiomyopathy.  
            We measured heart mass with two methods: calculation of left ventricular mass 
by 2D echocardiography and organ weight at necropsy. For each animal, we normalized 
heart mass to the lean body mass. While the A, B6, and FVB mouse strains had similar 
cardiac mass by the 16th-month time point, the BALB mouse strain had considerably 
more massive hearts, as demonstrated by both heart weight and LVM (Figure 2.7a-d). 
We monitored changes in cardiac structure and function by 2D echocardiography and 
observed a progression toward dilated cardiomyopathy (DCM) among the BALB males 
(Figure 2.7e), defined by an extreme increase in LVID, reduced systolic function, gross 
spherical (globular) shape, and cardiomegaly. The results confirm previous reports that 
the BALB genetic background is genetically predisposed toward development of dilated 
cardiomyopathy. Interestingly, male mice clearly demonstrated the DCM phenotype, 
whereas the female mice did not (Figure 2.7). The BALB male hearts that displayed the 
DCM phenotype exhibited a 2-fold increase in Timp1 gene expression and a 10-fold 
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increase in Spp1 gene expression when compared to the control (Figure 2.7g). Timp1 is a 
tissue inhibitor of matrix metalloproteinases (MMPs) which are involved in breaking 
down the LV myocardial collagen matrix.  
 
Treatment with AG1478 exacerbates severity of dilated cardiomyopathy 
A subgroup of the study population, the BALB/cJ males, demonstrated 
sensitivity to the therapeutic dose (144 mg/kg) of AG-1478 but not to the sub-therapeutic 
doses (data not shown). During age-related progression toward increased heart mass, 
there is a statistical difference between control and therapeutic-level treatment at the 8th-
month time point, in which the treatment mice had a larger average LVM (p < 0.05; 
Figure 2.7f). This trend persisted from the 8th-month forward, although there was a large 
statistical variation within the treatment group in the 12 and 16th month time points. The 
variation was large enough to not yield statistical significance, but the upward trend was 
clearly maintained, showing that treatment BALB/cJ males had greater increases in 
LVM compared to control mice.  Correlation analysis revealed a positive correlation 
between dose and two components of LVM, the LV anterior wall (r = .20, p < 0.05) and 
posterior wall (r = .23, p < 0.05; Supplementary Figure 2.2). At necropsy, the hearts 
from the therapeutic-level treatment group had significantly increased weight compared 
to the control group (p < 0.01; Figure 2.7b), supporting the trend that the treatment group 
accumulated more mass than the control, although the frequency of dilated 
cardiomyopathy is similar among both dose groups (Figure 2.7h). Hearts that displayed 
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the DCM phenotype also exhibited a 2-fold increase in Timp1 and a 10-fold increase in 
Spp1 gene expression (Figure 2.7g) when compared to normal hearts (without DCM).  
Considerations about timing of treatment: impact on weight 
We measured body weight and composition at 4-month intervals during the 16-
month duration of the study and compared the 5, 50, and 144 mg/kg dose groups to the 0 
mg/kg control per sex and strain. We found no significant statistical trends, using both 
ANOVA per time point and linear regression with time as the X variable. This is in 
contrast to findings by Barrick et al. (2008), who reported that wild-type C57BL/6J 
female mice (but not male mice) had reduced weight gain over the course of 90 days of 
treatment with 144 mg/kg of AG-1478. Since our experimental design consisted of 
gathering data in 4-month intervals (i.e. we did not record data in the time between 0 to 
approximately 120 days of treatment) and Barrick et al. (2008) showed that the 
difference between treatment and control female mice was significant between 20-60 
days of treatment but non-significant at 90 days (where the weight-time points began to 
merge), we conclude that any mild effects on weight gain are temporary and normalize 
over time. The temporary nature of this effect may be due to initial effects of treatment 
followed by adaptation of the organism or by an effect that is dependent on whether the 
mice were at the young adulthood period in which they gained weight, presumably 
before they were 120 days old. The Barrick et al. (2008) study, as with the present study, 
commenced treatment when the mice were approximately 8 weeks of age. This means 
that the timelines are comparable and demonstrates that the 20 to 60-day window of 
significant reduction in weight gain was not captured in our current study. We 
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demonstrate that after 8 months, there is little change in weight (Figures 2.8-2.10) and 
that the most rapid increase in both weight and fat mass occurred within the first 4 
months of treatment (approximately the first 130 days of age), indicating that the impact 
of EGFR inhibition on the physiology of weight gain may be dependent on the age of the 
mice, specifically on whether the mice are less than 130 days old and are in the period of 
their lives when they are gaining weight rapidly. A follow-up experiment that measures 
weight gain at regular intervals over the course of the first 130 days of age would aid in 
demonstrating that weight gain is reduced in the treatment group temporarily but 
normalizes with time. In addition, having a separate cohort of mice who are introduced 
to AG1478 treatment as older adults, at least 130 days of age, would aid in confirming 
whether the temporary effect is dependent on age or initial physiological response to 
treatment. This discrepancy would be important in identifying whether EGFR inhibitors 
are safe to administer to young adults (former hypothesis). If there is an initial weight 
loss response (latter hypothesis), there should be as assessment for whether a patient 
who is already underweight (as is common with cancer treatments) should be considered 
for treatment or given supplements to prevent the initial weight reduction. Weight loss is 
a commonly reported side effect of EGFR TKIs, and has recently been associated with 
reduced survival among patients with non-small cell lung carcinoma (Lin et al., 2018). 
 
Treatment with AG1478 had no impact on survival 
            We saw no significant differences in survival (Kaplan-Meier curve) among 
treatment groups when separated by strain and sex (Figure 2.11). We aimed to maintain 
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a sample size of at least 10 of the original 20 mice per treatment group (per strain and 
sex) for the 16-month duration of the study and were able to meet this goal. However, 
the BALB and FVB males had markedly higher mortality rates than the other strain/sex 
groups.  
 
Splenomegaly in BALB/cJ males with dilated cardiomyopathy 
Differences in genetic-dependent immunology is a major determinant of heart 
disease outcome, with BALB/cJ being naturally at higher risk for DCM (Nishimura et 
al., 2001; Huber & Lodge, 1986; Li et al., 2012; Liao et al., 2005). Liao et al. (2005) 
linked the development of DCM in BALB/cJ male mice to a heightened B lymphocyte-
mediated response when mice were exposed to human ADP/ATP. The membrane bound 
protein programmed cell death (PD1) plays a role in preventing autoimmunity by 
inhibiting T cell activity. PD1-deficient BALB/cJ mice also had higher rates of DCM, 
heart failure, and mortality compared to the PD1-deficient C57BL/6J mice (Nishimura, 
2001). Overall, there is a convincing connection between inappropriate immune 
response and development of DCM. Since the BALB/cJ genetic background is much 
more sensitive to autoimmune disorders in terms of development of DCM, we examined 
mouse spleens for potential abnormalities that could correlate to DCM incidence. Spleen 
weights and length were significantly high for C57BL/6J and BALB/cJ male mice 
treated with 144 mg/kg of AG1478, in comparison to their corresponding controls 







Our results showed that the BALB/cJ and C57BL/6J genetic backgrounds had an 
inherent tendency toward cardiomegaly and dilated cardiomyopathy (DCM) although the 
BALB/cJ background showed a greater propensity. This is consistent with previous 
studies showing that the BALB/cJ and C57BL/6J mouse strains are at high risk for 
developing DCM when exposed to known contributing factors of DCM, such as 
doxorubicin and Angiotensin II-dependent hypertension (Liu et al., 2012; Peng et al., 
2012, Peng et al., 2016). Furthermore, previous studies also indicate that BALB/cJ male 
mice fare worse than C57BL/6J males in terms of development of DCM and ensuing 
mortality rates. We saw a 2-fold increase in Timp1 and a 10-fold increase in Spp1 gene 
expression. Timp1 has been reported to be overexpressed by at least 500% in human 
hearts with severe DCM (Thomas et al., 1998). Spp1 is known to play a role in 
inflammation and autoimmunity and to be highly expressed in the DCM heart. Spp1 
expression has been shown to induce inflammation and fibrosis, which are permissive to 
the development of DCM and heart failure (Renault et al., 2010). 
The BALB/cJ strain was the only genetic background with a statistically 
significant difference between treatment (144 mg/kg) and control, in which the treatment 
group had exacerbated accumulation of LVM. Global longitudinal strain (GLS) and 
strain rate, used to detect subclinical changes in myocardial movement during anti-
cancer treatment (Thavendiranathan et al., 2014; Zeglinski et al., 2011) did not reveal 
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significant trends between control and treatment groups for any of the genetic 
backgrounds (data not shown). Our results indicate that individuals at risk for DCM (or 
have pre-existing DCM) had more severe accumulation of left ventricular mass (LVM) 
in conjunction with use of AG1478 as evidenced by M-mode 2D echocardiography. The 
consensus in the literature and medical field is that small molecule inhibitors of EGFR 
do not show significant cardiotoxicity or if there is toxicity it is too subtle to report. Here 
we demonstrate that a subgroup in the population, those at risk of DCM, may experience 
severe adverse effects to EGFR inhibitors. 
 Cardiotoxicity induced by chemotherapeutics are most common with pre-existing 
cardiovascular conditions. DCM is a common cause of heart failure and has a strong 
genetic component, with approximately 20-35% of cases being of familial origin (Maron 
et al., 2006). The population incidence of DCM is estimated to be 4.5 cases per 100,000 
people (Rakar et al., 1997). DCM has mixed causes, which include genetic mutations, 
autoimmune disorders, chemotherapeutic agents (doxorubicin and daunorubicin), and 
metabolic disorders. Li et al. (2012) showed that in a mouse model of human inherited 
DCM (deletion of Lys210 in cardiac troponin T) that utilized the BALB/cJ and 
C57BL/6J mouse strains, the greater severity of DCM in the BALB/cJ background was 
partly mediated by targeting the BALB/cJ-specific loss of function mutation in the 
tryptophan hydroxylase-2 gene (C1473G) involved in serotonin regulation. The 
serotonin reuptake inhibitor, paroxetine, reduced the BALB/cJ elevated levels of Akt, 
p38, and Serca2a (which can be used as a proxy of ERK activity) myocardial gene 
expression to levels comparable to C57BL/6J and improved overall symptoms of heart 
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failure (Li et al., 2012). AKT is known to be involved in physiological response to stress 
and exercise by compensatory cardiac hypertrophy (Kenessey & Ojamaa, 2006; 
Kinugawa et al., 2005), p38 MAPK is involved in pathological hypertrophic response, 
and ERK has been shown to be protective against eccentric hypertrophy (Kehat et al., 
2011). The propensity of BALB/cJ to upregulate pathways that are part of the canonical 
EGFR signal transduction cascade may indicate hyperactivity of EGFR, also potentially 
linked to the fact that poxvirus (which maintains EGFR activity by prevention of 
receptor recycling) is a known contributor to DCM development. The fact that the 
AG1478 EGFR inhibitor in our study exacerbates the DCM phenotype suggests that 
BALB/cJ is able to activate potent alternative pathways in the presence of EGFR 
inhibition.  
During baseline echocardiographic measurements, we observed consistent 
differences between mouse strains, indicating the significance of genetic background in 
determining normality (Figure 2.1; Table 2.1). Our results show that there is significant 
variability in the values of heart dimension and function among mouse strains and that 
separation by strain is an important factor to consider during analysis for each 
experiment. The aging process can also impact sensitivity to dosage and is in itself 
indicative of underlying differences in genetic architecture to how the heart responds to 
stress – an indication that there is an inherent difference in how the heart might respond 
to treatment in relation to changes due to aging. 
 Differences due to strain and sex were reduced when normalized to lean mass, 
but some differences remained, highlighting the importance of genetics and sex in 
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animal modeling. Males had higher absolute CO than females, but the relationship was 
inversed when normalized to lean mass. Overall, lean mass was more highly correlated 
with heart parameters than either fat mass and body weight, a similar trend to what has 
been reported in other studies (Collis et al., 2001), given that lean mass is metabolically 
active and therefore correlated to the oxygen demands that influence CO.  
           Histopathological examination did not reveal any significant dose-dependent 
toxicological patterns. Overall, these findings support the idea that EGFR TKIs pose 
little cardiotoxicity risk in chronic clinical use. However, individuals with dilated 
cardiomyopathy should be closely monitored for signs of aggravated hypertrophy while 
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Figure 2.1. Genetic background-dependent differences in baseline 
echocardiographic parameters. Echocardiography B-mode and M-mode imaging of a 
representative male per mouse strain. The left ventricular endo and epicardium are traced in blue. 
The scale bar signifies 1 mm, and the dot indicates the orientation of the transducer (the blue dot 
is closer to the cranial end). The two-sided arrow indicates a phenotypic spectrum in cardiac 
lumen volume and wall thickness, in which the top two mouse strains have greater left 
ventricular diameters and blood volume while the bottom two mouse strains have smaller left 
































Figure 2.2. Age-related cardiovascular changes vary by genetic background. (a) Cross sectional and 
transverse views used to analyze left ventricular structure and function. (b-c) Changes in cardiac structure and 















Variable A/J BALB/cJ C57BL/6J FVB/NJ
LVM (mg) 100 216 195 94
LVID (mm) 27 92 110 0
LVAW (mm) 19 43 38 33
LVPW (mm) 15 8 0 25
CO (mL/min) 18 59 100 -21
SV (uL) 29 50 145 -20





Figure 2.3. Age-related changes in cardiac function and structure in the A/J genetic 






































































































































Figure 2.4. Age-related changes in cardiac function and structure in the BALB/cJ 






































































































































Figure 2.5. Age-related changes in cardiac function and structure in the C57BL/6J 







































































































































Figure 2.6. Age-related changes in cardiac function and structure in the FVB/NJ 





































































































































Figure 2.7. Treatment with AG1478 exacerbates severity of dilated cardiomyopathy. Ratio of heart weight 
to lean mass at necropsy for (a) female (n ≥ 11) and (b) male (n ≥ 8) mice. Ratio of left ventricular mass 
(obtained by echocardiography at the 16th-month time point) to lean mass for (c) female (n ≥ 5) and (d) male (n 
≥ 5) mice. (e) Echocardiography B-mode imaging of the longitudinal axis of a representative BALB/cJ male 
(144 mg/kg treatment group) across three time points, displaying progression of dilated cardiomyopathy. The 
blue scale bar indicates 1 mm. (f) Changes in the ratio of left ventricular mass to lean mass across time points. 
BALB/cJ male mice in the control and 144 mg/kg treatment groups are compared (n ≥ 5). (g) Fold change in 
expression of Timp1 and Spp1 for BALB/cJ male hearts grouped by normal versus dilated cardiomyopathy 
phenotypes (n ≥ 5). (h) Frequency of the dilated cardiomyopathy phenotype among BALB/cJ males in the 
control and 144 mg/kg treatment groups (n ≥ #). (i) H&E stained longitudinal and short axis sections of heart 








































































































































































































































































Figure 2.8. No significant changes in body and fat mass. Comparison of control versus 
treatment groups, separated by sex. Changes in body weight and fat mass (±SEM) for (a-b) all 






























































































Figure 2.9. No significant differences in body weight and fat mass among female mice separated by strain. 
Mean body weight and mean fat mass (±SEM) for (a) A/J females (n = 19-20), (b) BALB/cJ females (n = 19-
20), (c) C57BL/6J females (n = 19-20), and (d) FVB/NJ females (n = 20).  





































































































































































Figure 2.10. No significant differences in body weight and fat mass among male mice separated by strain. 
Mean body weight and mean fat mass (±SEM) for (a-b) A/J males (n = 19-20), (b) BALB/cJ males (n = 18-20), 
(c) C57BL/6J males (n = 20), and (d) FVB/NJ males (n = 17-20). 









































































































































































Figure 2.11. Kaplan-Meier survival curves for mice separated by strain and sex. (a-
b) A/J female and male mice, respectively. (c-d) BALB/cJ, (e-f) C57BL/6J, (g-h) 
FVB/NJ. 










































































































































Figure 2.12. Increased splenomegaly among treated mice. Comparison between 
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CHAPTER III  
INHIBITION OF EGFR BY AG1478 REDUCES INCIDENCE OF SPONTANEOUS 
PULMONARY ADENOMAS IN A/J FEMALE MICE 
 
 Introduction 
 The epidermal growth factor receptor (EGFR) is one of four members of 
the ERBB family of tyrosine kinase receptors, which consists of EGFR (ERBB1/HER1), 
ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4). The ERBB receptors are critical 
for tissue development and cell maintenance due to their roles in mediating cellular 
proliferation, differentiation, inhibition of apoptosis, and migration. EGFR stands out 
from its family members in that it has full activation and auto-inhibitory functions 
(unlike ERBB2 and ERBB3) and has its unique set of ligands and tyrosine residue 
docking sites. This unique genetic and biochemical makeup of EGFR makes it a potent 
promoter of tumorigenesis. Overexpression of EGFR and/or its activity is present in 
many types of cancers including lung squamous-cell carcinoma (85% of cases), 
colorectal (75%), breast (>50%), prostate (41-100%), glioblastoma (60%), and epithelial 
head and neck cancers (80-100%) (Chakraborty et al., 2014; de Castro-Carpeño et al., 
2008; Di Lorenzo et al., 2002; Eze et al., 2017; Masuda et al., 2012; Vavala, 2017; Xu et 
al., 2017). Given that carcinomas account for 80-90% of cancers and that EGFR 
misregulation is prevalent in about one-third of carcinoma cases (Mendelsohn, 2002), 
there has been much effort in targeting EGFR for anti-cancer therapy. Treatment 
strategies include antibodies that target the receptor's ligand binding domain, small 
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molecular tyrosine kinase inhibitors that compete with ATP at the kinase domain, and 
EGF-targeted immunotherapy. The prevalence of aberrant EGFR activity in human 
cancers has made EGFR-targeted mono or combinatorial therapies common strategies 
for inhibiting tumor growth (Han et al., 2005; S. Wang et al., 2018). With lung cancer in 
particular, EGFR-targeted therapy has become a front-line treatment. 
 Lung cancer is the leading cause of cancer deaths worldwide. EGFR activating 
mutations are particularly common in both non-small cell lung carcinoma (NSCLC) and 
squamous cell carcinoma, which combined account for 85-90% of lung cancer cases. 
Approximately 10% of lung tumors in the North American population have an EGFR 
mutation (Graham et al., 2018). This frequency can be much higher in other regions, 
with approximately 50% of tumors in Southeast Asian patients having mutations in the 
EGFR gene (Graham et al., 2018; Shi et al., 2014; Shigematsu et al., 2005; Wieduwilt & 
Moasser, 2008). In a study encompassing several countries, Shigematsu et al. (2005) 
reported that 21% of NSCLC samples had EGFR activating mutations. Non-smoking 
East Asian females with adenocarcinoma have a particularly high incidence of activating 
EGFR mutations (Shigematsu et al., 2005; Sholl et al., 2009) and this group tends to 
respond favorably to EGFR-targeted therapy compared to other ethnicities (Yang et al., 
2014). 
 EGFR-targeted treatments, such as with tyrosine kinase inhibitors (TKIs), 
eventually fail due to the emergence of additional mutations that are resistant to the 
original treatment. For instance, NSCLC patients eventually develop resistance to first 
generation EGFR TKIs (such as gefinitib and erlotinib). The T790M EGFR missense 
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mutation (at exon 20) is responsible for more than 60% of resistant cases (Yu et al., 
2013). The T790M residue confers a greater affinity to ATP and is able to compete with 
EGFR TKIs and thus evade their inhibitory actions. Even with third generation TKIs 
(such as osimertinib and olmutinib) that are designed to overcome T790M resistance by 
forming covalent bonds at the residues, resistance typically re-emerges via the C797S 
missense mutation which disrupts the covalent bonds. Fortunately, the C797S mutation 
is sensitive to first generation TKIs and combinatorial therapy of first and third 
generation TKIs has been shown to be effective in treating T790M/C797S dual mutants 
(Kobayashi & Mitsudomi, 2016; Li et al., 2017).  
  Initially effective treatments may eventually fail due to late detection of cancer 
and corresponding tumor heterogeneity (Casás-Selves & DeGregori, 2011; Frank & 
Nowak, 2004; Merlo et al., 2006). Chance mutations can confer non-regulated growth 
and proliferation of a cell subpopulation. Additional mutations (that discourage 
apoptosis, evade the immune system, and enhance proliferation) are more likely to 
accumulate as the cell line expands rapidly and undergoes more mitotic events. By the 
time that the tumor is detected and treatment commences, subclonal groups of cells 
resistant to treatment may already exist. Targeted-therapies may initially treat a large 
portion of the cancer cell population. However, treatment may inadvertently add 
selective pressure that results in rapid adaptation of the tumor in favor of the resistant 
clones. Conversely, early stage cancers tend to be more homogeneous and respond more 
favorably to treatment. Overall, early detection and preventative methods are key to 
avoiding the risks associated with tumor heterogeneity.  
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 There is some evidence that EGFR may be a good target for cancer prevention. 
Among cases of lung adenocarcinomas with EGFR mutations, 43% of patients also had 
EGFR mutations in adjacent normal lung epithelium (Tang et al., 2005), suggesting that 
EGFR mutations are present in the early stages of tumorigenesis and that preventative 
treatment may suppress expansion of these rogue cells. Several studies have reported 
significant reductions (50-90%) in tumor load in mouse models of colorectal cancer 
when EGFR activity was inhibited (Rinella & Threadgill, 2012; Roberts et al., 2002; 
Torrance et al., 2000). This is in stark contrast to efficacy rates seen in the clinic, where 
about 10% of colorectal cancer patients respond to EGFR-targeted treatment (Troiani et 
al., 2016). We hypothesize that the timing of treatment explains the discrepancy between 
preclinical and clinical success rates. Resistance to EGFR-targeted treatment has 
multiple causes, including upregulation of redundant pathways (such as activating 
mutations in the KRAS gene or overexpression of the insulin growth factor receptor 1) 
and the emergence of mutant EGFR receptors that have acquired resistance to the 
particular chemotherapeutic (such as the T790M mutation in NCSLC). Unlike in 
preclinical trials, EGFR-targeted therapy commences in the clinic after tumors are 
established. This difference in timing may correspond to the decreased effectiveness 
observed in the clinic and indicates potential use of EGFR inhibition for cancer 
prevention. The topic of cancer prevention by targeted therapy has been explored in 
breast cancer prevention research (den Hollander et al., 2013). Tamoxifen and raloxifene 
in particular, which target the estrogen receptor, were tested in several clinical trials with 
women who did not have breast cancer in order to evaluate its potential use as a 
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chemopreventative agent. Trials were largely beneficial at preventing ER-positive cancer 
(reviewed by den Hollander et al., 2013) and it is now used clinically for 
chemoprevention in high risk individuals. The EGFR/ERBB2 dual inhibitor lapatinib 
and the EGFR TKI gefinitib were shown to greatly delay development of ERBB2-
overexpressing mammary tumors in mice, in which gefitinib delayed onset of cancer to 
310 days of age compared to 140 days observed in non-treated mice (Lu et al., 2003). 
Taken together, targeting the commonly disrupted EGFR network could be immensely 
beneficial since rogue cells would have a reduced chance of gaining access to 
uncontrolled growth and thus have a smaller chance of acquiring additional mutations 
that confer a selective advantage.  
 Preclinical studies have shown that AG1478 is a promising candidate for 
therapeutic use due to its high specificity to EGFR and its efficacy at reducing tumor 
growth in cancer cell lines and mouse models (Ellis et al., 2006; Johns et al., 2003; 
Rinella & Threadgill, 2012). Furthermore, even a subtherapeutic dose of AG1478, in 
combination with radioimmunotherapy, was shown to be effective in inhibiting growth 
of human squamous cell carcinoma cells in vitro (Lee et al., 2005). In the current study, 
we tested the effectiveness of AG1478 in preventing the spontaneous occurrence of 
various neoplasia (as modeled by four inbred mouse strains with different genetic 






Materials and Methods 
Animals and Husbandry 
We obtained mice that were 6-to-8-weeks-old (A/J, BALB/cJ, C57BL/6J, and 
FVB/NJ strains) from The Jackson Laboratory (Bar Harbor, ME). There were 160 mice 
per strain, 80 males and 80 females, to equal a total of 640 animals on study. Baseline 
measurements were taken after one week of acclimation to the facility and treatment 
commenced at ages 8-10 weeks. Animals were measured for all parameters at 4-month 
intervals, yielding a total of 5 time points (0, 4, 8, 12, and 16 months), with some time 
points omitted for particular parameters as noted in the corresponding sub-methods 
sections. The mice were housed 5 per cage, in Nextgen filtered cages, at 22° C under a 
12-hour light/dark cycle. In all our experiments, we adhered to Animal Use Protocols 
approved by the Texas A&M University Institution Animal Care and Use Committee. 
Mice were euthanized by carbon dioxide asphyxiation and immediately necropsied. 
Tissues were either flash frozen in liquid nitrogen or fixed in formalin.  
 
Diet and Delivery of AG1478 
Tryptosin AG-1478 was purchased from LC Laboratories (Woburn, MA) and 
incorporated into Western Diet mouse chow (D12079B) by Research Diets, Inc. (New 
Brunswick, NJ). The therapeutic-level dose chosen was 144 mg of AG1478/kg of food, 
shown to be sufficient to inhibit EGFR phosphorylation (Barrick et al., 2008; Rinella & 
Threadgill, 2012). The 50 mg/kg sub-therapeutic dose was selected due to its efficacy at 
inhibiting cancer cell growth at an equivalent dose in vitro (Lee et al., 2005), with the 
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lowest dose chosen to be 1/10th of the 50 mg/kg dose (i.e. 5mg/kg). The control chow (0 
mg/kg) consisted of the Western diet alone. Food dyes were added for ease of feeding 
purposes, and mice received food and water ad libitum.  
 
Histopathology 
 Lungs were removed and inflated with 10% formalin by injected into the trachea 
and were fixed in formalin for 48 hours before being stored in 70% ethanol until further 
processing and paraffin embedding. Five μm transverse sections were stained with 
hematoxylin and eosin (H&E). Soft tissue sarcomas, which were attached to surrounding 
muscoloskeletal tissue, were detached by scissors and then but by scalpel into three 
pieces so as to obtain a middle section that was representative of both the center and 
outer edges of the mass. Sarcomas were sectioned at 5 μm along the same plane as the 
dissection cut sites and H&E stained. 
 
Results  
Reduced incidence of pulmonary adenoma in A/J female mice. 
 The presence of surface pulmonary neoplasia was readily at necropsy. The 
frequency of neoplasia occurrence was based on the presence or absence of nodules 
upon visible examination during necropsy, regardless of nodule size or quantity (Figure 
3.1). Generally, a nodule-positive lung contained 1-3 nodules, each with a diameter of 
≤1 mm. Regions of neoplasia were identified as pulmonary adenomas by histological 
examination. Abnormal cells were generally cuboidal or columnar shaped and were 
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located on fibrovascular stromal tissue. Cells had irregularly oval nuclei, with dispersed 
chromatin and inapparent nucleoli, and no evidence of mitoses. The pulmonary 
adenomas were of benign nature. Other pathologies observed included pulmonary 
epithelial hyperplasia and bronchus-associated lymphoid tissue hyperplasia. FVB/NJ 
neoplasia frequencies were comparable to other reports showing that mice aged to 14 
months had a 13% and 26% frequency of pulmonary neoplasia among males and 
females, respectively (Mahler et al., 1996). BALB/cJ had moderate frequencies of 
neoplasia, as expected. C57BL/6J is widely reported to be resistant to developing lung 
neoplasia. Accordingly, we did not observe lung neoplasia among C57BL/6J mice. In 
general, the frequency of lung neoplasia was not affected by preventative treatment with 
AG1478 (Tables 3.1-3.3). However, the A/J female group treated with the therapeutic 
level dose of AG1478 (144 mg/kg) had a significant reduction in neoplasia frequency, 
with nodules observed in 18.8% of treatment mice and in 47.7% of control mice 
(Spearman's p = 0.04). It is possible that the relatively low frequency of nodules in the 
other mouse strains (as compared to A/J) were insufficient for adequate statistical 
analysis and that continued aging was necessary to increase neoplasia frequency.  
 
The occurrence of soft tissue sarcoma was unaffected by preventative treatment with 
AG1478. 
 Soft tissue sarcomas, which were obsereved only in the A/J mouse strain, were of 
an aggressively invasive and highly proliferative nature. Neoplastic masses were fast 
growing and generally measured about 2.5 cm in diameter at the time of necropsy and 
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occurred preferentially in the region of the hind limbs. Neoplastic tissue was observed 
infiltrating and replacing the local skeletal muscle and adipose tissue (Figure 3.2). These 
neoplasms were characterized histologically as being unencapsulated, poorly 
demarcated, and invasive. Neoplasm was composed of spindle cells arranged in 
haphazard streams at right angles supported by a scant amount of preexisting stroma, 
and often interposed between remaining skeletal muscle fibers and adipocytes. Cells had 
a small amount of pale eosinophilic cytoplasm, indistinct cellular borders, and oval to 
irregularly shaped nuclei with finely stippled chromatin and 1-3 large, prominent, 
basophilic nucleoli. Anisocytosis and anisokaryosis were marked and there were 
occasional very large multinucleated cells with more abundant eosinophilic cytoplasm 
and up to approximately 30 oval nuclei, often arranged around the periphery of the cell. 
Mitoses ranged from 4 to >10/hpf (400x), indicating high levels of proliferation. We 
observed neoplasms that were well vascularized with irregular capillaries in several 
areas and large areas of necrotic debris. The frequency of spontaneous soft tissue 
sarcoma did not significantly vary by preventative treatment with AG1478 (Table 3.4). 
 
Discussion 
 The observed pulmonary adenomas had benign features of well delineated 
demarcation and few to no mitoses. This type of adenoma was unlikely to have 
progressed to malignancy (Meuwissen & Berns, 2005; Nikitin et al., 2004). Epithelial 
hyperplasia was also observed, often within the same sample containing an adenoma. 
Reports in the literature have suggested that hyperplasia and benign adenomas can be a 
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continuum along a shared process (Derwahl & Studer, 2002), possibly explaining why 
we frequently observed the two pathologies within the same tissue.  
 The present study demonstrates a proof of concept that a genetic background 
highly susceptible to pulmonary neoplasia can benefit from chemopreventative targeted 
therapy. We observed high instances of pulmonary adenomas among A/J mice, more 
moderate incidence in BALB/cJ, much less pronounced frequency in FVB/NJ, and no 
cases of adenomas among the C57BL/6J mice. These findings are in agreement with 
existing literature that susceptibility to developing both spontaneous and induced lung 
neoplasia is highly mouse strain-dependent, involving complex interactions among many 
genes (Lemon et al., 2002; Meuwissen & Berns, 2005). A/J female mice are also highly 
susceptible to developing adenocarcinoma (Meuwissen & Berns, 2005; Gordon & 
Bosland, 2009) and have been the subject of several prevention studies (Patlolla et al., 
2015; Rahmani et al., 2015). Overall, A/J female mice are a good model for individuals 
at high risk for various cancers. 
 Our findings indicate that EGFR activity may be involved in the development of 
pulmonary adenoma in the susceptible A/J genetic background. It is clear that there are 
genetic factors that contribute to lung cancer risk. EGFR variant alleles have been 
reported to be involved in familial cases of NSCLC (Kanwal et al., 2017). Furthermore, 
upregulation in expression and/or activity of EGFR, KRAS, and downstream ERK are 
common features of adenocarcinoma that are also observed in mouse models (Mervai  et 
al., 2018; Yamakawa  et al., 2016; Sartori  et al., 2008). 
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 There are currently no effective targeted treatments for soft tissue sarcomas. 
Treatment strategies consist mainly of surgical removal of tumor in conjunction with 
chemo and radiotherapies. EGFR and other genes in the EGFR network are highly 
expressed in human soft tissue sarcoma, but EGFR inhibitors have not been an effective 
mode of treatment for these cancers. A recent study showed that phosphorylated EGFR 
and downstream phosphorylated ERK were correlated with sarcoma progression 
whereas overexpression of these and other EGFR pathway genes were not correlated 
(Yang  et al., 2017). Our findings demonstrate that while A/J mice are prone to 
developing fast growing soft tissue sarcomas, preventative EGFR-targeted treatment did 
not have a significant effect on tumor frequency. Although the outcome was unexpected, 
our findings are in agreement with human data indicating that soft tissue sarcomas are 
largely irresponsive to EGFR inhibitors. The A/J mouse strain appears to be a good 
model for sarcoma. Our findings support the utility of this mouse model as a way to 


















Figure 3.1. Reduced incidence of pulmonary adenoma in A/J female mice. (a) 
Frequency of pulmonary adenomas after 16 months of treatment with 144 mg/kg of AG1478. 
Tumor frequencies were based on (b) visible nodules recorded during necropsy. (c-d) An 
approximately 1mm diameter, well demarcated unencapsulated expansile adenoma on a 












































Figure 3.2. Fast growing smooth muscle sarcoma in a representative A/J mouse. (a) 
Spindle cells arranged in perpendicular streams and bundles (100x). (b) Large areas of necrosis 
characterized by complete loss of cellular detail and replacement with pale eosinophilic granular 
material. Large multinucleated cells are visible (100x). (c) Neoplastic cells infiltrating and 









Table 3.1. Pulmonary adenoma frequency for A/J mice. Tumor frequencies were based 
on visible nodules recorded during necropsy. Dose groups were compared to their corresponding 




















Table 3.2. Pulmonary adenoma frequency for BALB/cJ mice. Tumor frequencies were 
based on visible nodules recorded during necropsy. Dose groups were compared to their 




















Table 3.3. Pulmonary adenoma frequency for FVB/NJ mice. Tumor frequencies were 
based on visible nodules recorded during necropsy. Dose groups were compared to their 



















Table 3.4. Sarcoma frequency for A/J mice. Tumor frequencies were based on visible 
nodules recorded during necropsy. Dose groups were compared to their corresponding control 
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CHAPTER IV  
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
The epidermal growth factor receptor (EGFR) is essential for cell growth and 
survival. EGFR signaling is widely misregulated in diseases, often by overexpression of 
the EGFR gene or by hyperactivity of the receptor. Abberant EGFR signaling is 
implicated in early stages of human breast and lung cancers (den Hollander et. al., 2013; 
Tang et. al., 2005) as well as in mouse models of colorectal cancer (Roberts et al., 2002). 
Since early stage cancers are often homogenous and more readily treatable, we sought to 
to understand whether EGFR-targeted treatment was effective for chemoprevention. Our 
animal model consisted of genetic strains (A/J, BALB/cJ, C57BL/6J, FVB/NJ) with 
familial histories of high rates of spontaneous neoplasia. Our animal models reflected the 
situation in which groups of people have strong familial histories of developing cancer 
but do not have detectable mutations or pre-existing lesions.  
Overall, our animal models had lower rates of neoplasia than expected, compared 
to historical frequencies reported in the Jackson Laboratory mouse database. We 
conclude that mouse strains likely experienced genetic drift before the standardization of 
cryopreservation techniques at animal facilities and that our findings represent current 
neoplasia rates. We measured the frequencies of neoplasia and compared the treatment 
groups to the non-treated control for each mouse strain. Our analyses focused on 
pulmonary adenomas and soft tissue sarcomas since these neoplasias occurred at the 
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highest rates. Our findings indicate that EGFR-targeted treatment did not reduce 
incidence of spontanous lung adenoma or soft tissue sarcoma. We conclude that 
preventative treatment with an EGFR pharmaceutical inhibitor is not effective at 
reducing cancer rates in a model of familial predisposition toward cancer. Our findings 
contrast with previous research with the ApcMin/+ colorectal cancer mouse model in 
which reduced EGFR activity effectively reduced the number of small intestinal polyps 
(Roberts et. al., 2002). We conclude that although EGFR-targeted therapy is not 
beneficial for groups with familial predispositions to cancer, individuals with specific 
mutations, such as in the APC gene, may benefit from chemopreventative treatment.  
As EGFR-targeted treatment becomes more widely used in the clinic, there is an 
increasing need to understand how differences in genetic background contribute to 
treatment response. We do not currently know the clinical rate of cardiotoxicity response 
to EGFR inhibitors. Our findings demonstrate that a genetic background predisposed to 
developing dilated cardiomyopathy, the BALB/cJ mouse strain, is at risk of adverse 
effects from treatment with the EGFR inhibitor AG1478. BALB/cJ male mice had an 
exacerbated increase in left ventricular mass and weight, suggesting that EGFR plays a 
role in the heart's adaptation to stress. There is a need for future experiments focused on 
how allelic differences between mouse strains determine cardiotoxicity outcome in 
response to EGFR-targeted therapy. Such a direction would aid in identifying risk 
factors present in the BALB/cJ genetic background that may be translatable to 




 Future Directions 
            As EGFR-targeted therapies are becoming more commonly used in the clinic for 
treatment of various cancers, there is an increasing need to understand potential adverse 
consequences to treatment. Despite the fact that EGFR mediates intracellular signaling 
pathways known to be involved in cardiomyopathies (Peng et al. 2016; Thomas et al., 
2002; Kagiyama et al., 2002; De Pasquale et al., 2018; Schreier et al., 2013; Haq et al., 
2001; Howes et al., 2006), cardiotoxicity response rates to EGFR-targeted treatments are 
currently unknown. We report that individuals at risk of developing dilated 
cardiomyopathy (DCM), the BALB/cJ male mice, may also be at risk for further 
increase in heart mass and cardiomyopathy progression. Our central hypothesis for a 
future study is that polymorphisms in the BALB/cJ genome combined with reduced 
EGFR signaling is conducive to progression of dilated cardiomyopathy. We propose to 
test the hypothesis by the following aims: 1) Generate mice with genetically inducible 
reduction in EGFR activity, 2) chemically induce DCM in mice from Aim 1 and 
compare mouse strains for severity of DCM phenotype, and 3) identify quantitative trait 
loci (QTL) in the BALB/cJ genome that contribute to sensitivity to reduced EGFR 
signaling.  
            The goal of Aim 1 is to generate a genetic model of pharmaceutical inhibition of 
EGFR. The creation of a genetic model is justified because it would eliminate the 
confounding variable of off-target effects from pharmaceutical inhibitors, in which 
inhibitors may bind to other tyrosine kinases in addition to EGFR. The genetic model 
would consist of mice heterozygous for EGFR variants: the hypomorphic allele EGFRwa2 
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and the inducible cre-lox allele EGFRtm1Dwt. The focus of Aim 2 is to induce DCM in 
two strains of male mice with potentially contrasting responses, BALB/cJ and C57BL/6J 
(Figure 4.1). Other groups have shown that DCM can be chemically induced by 
treatment with doxorubicin or, alternatively, by angiotensin-II (Liu et at., 2012; Peng et 
al., 2011). When comparing DCM outcome between the two mouse strains, we expect 
BALB/cJ EGFRtm1Dwt/wa2 mice treated with cre-recombinase to have a more severe DCM 
phenotype, with greater left ventricular mass, compared to the other experimental groups 
(Figure 4.1). The goal of Aim 3 is to identify QTLs involved in DCM outcome that are 
also dependent on EGFR activity level. The long-term goal is to identify genes that 
interact with EGFR within a network that mediates how the heart responds to stress in 
terms of dilated cardiomyopathy progression. Identification of these genes and 
polymorphisms that contribute to network interactions would aid in developing genetic 











Figure 4.1. Diagram for future works. BALB/cJ and C57BL/6J mice have a inducible 
reduction in EGFR activity via a combination of the hypomorphic EGFRwa2 allele with 
the EGFRtm1Dwt conditional knockout allele. One group of mice per strain is treated with 
cre-recombinase. Dilated cardiomyopathy is induced among all mice by injections with 
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